Good morning, and welcome everybody here in our headquarters in Lübeck, and also a warm welcome to everybody watching this event online. My name is Thomas Fischler. I am responsible for Investor Relations and treasury here at Dräger, and I have the pleasure to guide you through today's program. First of all, thank you very much for your interest in Dräger, and also thank you very much for investing your time today to spend this day with us and giving us the chance to explain our Ambition 2030 with you. Today, we will be talking about our Ambition 2030, that is, how we want to grow over the next five years and how we intend to improve our profitability on this journey. Obviously, all of the material that we will be presenting today will be shared with you on our website right after the event.
While reading through the materials, please do take note of our legal disclaimer, which is on page number two. Now, let me introduce to you our today's speaker. Let me start with the Chairman of the Board, Stefan Dräger. Mr. Dräger is joined by Gert-Hartwig Lescow, Deputy Chair, CFO, responsible for finance and corporate IT. Next, we have Stefanie Hirsch. She is the responsible Board Member for Sustainability, for Quality Management, as well as for Human Resources. Then we move on to the businesses. We have for the Safety Division, the responsible Board Member, Rainer Klug. Next to him, Dr. Reiner Piske. He is the Global Responsible Board Member for Sales and Service for both divisions, Medical as well as Safety. Last but not least, Toni Schrofner, responsible Board Member for the Medical Division. Now, let's have a short look on our agenda for today.
We will kick off the day with a presentation of our group strategy by Stefan Dräger himself. Stefanie Hirsch will follow and explain why sustainability and quality management is so important for our success. We will then commence with our first deep dive into the business with Toni Schrofner and Reiner Piske explaining the Ambition 2030 of the Medical Division. This will be followed by our first Q&A session of the day. We will have three. This will be the first one. For all the participants online that are registered, you have a small chat window next to the stream where you can ask your question, and we will take questions here from the room as well as from the webcast.
After a short break, we will then go into the second deep dive into the Safety Division, where Rainer Klug and Reiner Piske will explain the division and the ambition of the division. After that, again, a short Q&A followed by a lunch break. We will rejoin at 1:45 P.M. for the kickoff of the afternoon session by Gert-Hartwig Lescow. He will then explain our financials, our capital allocation, as well as the outlook, followed by the final Q&A. Stefan Dräger, with his closing remarks, will end the formal part of the program. At this time, the webcast will end, but then we invite our guests here in Lübeck to come with us to the Design Center to meet our product specialists that have prepared some use cases for you to demonstrate real life some of the functionalities and things that we will be talking about today.
Without further ado, I hand over to the Chairman of the Board, Stefan Dräger.
Thank you. Thank you, Tom. A warm welcome to all of you, ladies and gentlemen. Together with my board colleagues, I would like to extend a warm welcome to you, and we really appreciate your participation, your coming to Lübeck, and you joining the webcast. This is our very first Capital Markets Day. We had originally planned the event many years ago, but there has never been a perfect time. In 2020 and 2021, all of our resources were used to master the COVID-19 pandemic and to seize the many opportunities that came with it. In 2022, we were held back by global supply chain disruptions, and since 2023, we have been shifting our focus from sales growth to earnings growth. This has paid off. In 2025, we not only delivered record net sales, but also a significant increase in earnings, despite some headwinds.
We are confident in delivering further improvement in 2026. This year is the perfect time to host a Capital Markets Day and to provide you with an ambition for the next years. We are also looking forward to our discussion. Let's get to our group strategy. As a leading manufacturer of medical and safety technology, we have a clear mission: turning technology into Technology for Life. That mission gives our business a clear purpose, and it also defines the standards our products have to meet. We have been doing those since 1889. For investors, the question is how we turn that purpose into sustainable value. Our answer begins with the strength of our technology and our customer relationships. We have a large installed base. We understand the applications in which our products are used, and we have service capabilities close to our customers.
We want to build on these strengths with more connected solutions and more recurring business. At the same time, we want to improve the efficiency of our operations. The combination should support stronger earnings and better returns on the capital we employ. Medical has a substantial opportunity to improve profitability. Safety can expand from an already strong earnings base. Both divisions must translate their opportunities into measurable customer value and attractive economics. This is the focus of our Ambition 2030. Today, we will explain the operating priorities behind the ambition, and we will also explain the financial discipline that connects growth, investment, and shareholder participation. With our strong offerings of Technology for Life, we are well-positioned to profit from future trends. Our main goal is to protect, support, and save lives. In doing so, we are committed to creating sustainable value for our stakeholders.
This not only includes customers, employees, or suppliers, but also shareholders. In order to achieve our vision, we have to complete our mission across many areas of application. As a specialist in acute care, we are committed in supporting hospitals in improving clinical outcomes, managing costs, enhancing patient experience, and ensuring staff satisfaction. That is why, for over 125 years, we have been passionate about developing technologies, products, training, and services for acute care that help you achieve our goals. Helping to reduce the number of preventable deaths in hospitals is a pledge that I made. My personal goal goes further, to improve acute care with technologies and services that lead to therapy assistance and ultimately to hospital automation. We protect those who risk their own lives to save others. This particularly includes firefighters, rescue services, and people who work in civil protection and disaster control.
We are helping the world move on one step closer to making Vision Zero a reality. As a part of this international initiative, we contribute to the aim of completely eradicating occupational accidents, promoting a healthy lifestyle as a preventive measure to avoid work-related illness, and encouraging individual well-being. We help deliver evidence quickly when time is of the essence. This is why authorities all over the world rely on our alcohol and drug testing devices. In 1953, we invented the Alcotest tubes, which allowed the police to detect alcohol in exhaled breath for the first time. Thanks to this pioneering achievement and continuous customer intimacy, we are now the global market leader in this field. We protect miners and keep them safe during their operations above or underground.
We have been doing this since my grandfather, Bernhard Dräger, invented the first reliable closed-circuit breathing apparatus for mine rescue teams more than 100 years ago, which enabled the profession of mine rescuers, who to this day proudly call themselves Drägermen in the U.S. and in Canada. Last but not least, we protect those who protect us. We bring over 135 years of experience to the defense and security sectors. From vehicle filters to diving equipment to breathing gas supply, our technology ensure the safety of operations on land, at sea, and in the air. This has become even more important since the war in Ukraine. These diverse areas of application highlight our diversified approach and exemplify our vision. We develop Technology for Life. Let me now take you on a deeper dive into our business model. With medical and safety, we have two divisions that might seem very different.
However, they build on the same engineering foundation. In 1889, our company founder, Johann Heinrich Dräger, invented the Lubeca valve, the first reliable reducing valve for carbon dioxide. The first patent for Dräger. Its technology laid the foundation for our later products, such as the mine rescue apparatus, anesthesia machines, and respiratory protection and gas detection equipment for miners and firefighters. Today, many of our core technology components are installed in devices across both divisions. For example, sensors are not only used in gas detection devices, but also in anesthesia machines to measure oxygen. Soda lime is used in anesthesia machines, mine rescue, and military diving. Today, technology is still very important for Dräger, as we file almost 100 patents every year. With the same core, we are serving many different markets.
For me, it is really important that today you understand that Dräger is not a conglomerate with diverse activities randomly bundled under the same brand. We have a shared technical base concentrated in several core technologies, which serve a multitude of our markets in both divisions. The evolution of the portfolio of technologies is closely linked to our leading idea, Technology for Life. Technology stands for engineering excellence, innovation, and technology push. Life stands for all the diverse applications and markets that we serve. We have always developed together with our customers. New applications have been explored with existing technologies and skills, and vice versa, new technologies have been added to the portfolio, serving customer needs. Behind this, both divisions share the same value-driven management. On the one hand, this is characterized by our corporate personality, the basis for how we act, make decisions, and work together.
On the other hand, it is characterized by our corporate objectives, which I will present in a few minutes. While both divisions have a lot in common, our company is also shaped by high diversity. This applies to business mechanics, divisions, markets, regions, customers, products, after-sales, applications, technologies, and innovations. This strong diversity becomes very visible with the following three indicators. First, no single customer makes up more than 1% of our net sales at Dräger. Second, no single product accounts for more than 3% of the company's net sales. Third, no more than 5% of purchasing volume can be attributed to a single supplier. This increases our resilience and opens the door to opportunities, and it enables us to react quickly and flexibly to changing market requirements, even more important in challenging and volatile times.
Our diversified business model enables us to provide answers for future trends and challenges, and these also provide strong tailwinds for our future growth. Our business is driven by demographic changes, increasing safety requirements, and rising healthcare complexity. At the same time, topics like defense, connectivity, climate change are becoming more important. We tackle these challenges by delivering Technology for Life. For the past decades, we have been very successful in turning megatrends into long-term growth. In most years, net sales recorded an increase, even in times of crisis. As well as we all know, there have been quite a few of these external shocks in the recent years. Despite that, in 2025, we reached a new record sales level of around EUR 3.5 billion. The same is true for our profitability. Over the years, profitability, that was volatile, and overall, it was too low.
We acknowledge this, and we want to change this, and we have therefore introduced our corporate objectives. Our corporate objectives set the strategic direction at Dräger. They describe what ensures our successful longevity. That is why we view these goals not as temporary initiatives, but rather as a permanent strategic framework. They have no end date. Here is an overview of our three corporate objectives. Profitability is our most important goal. It forms the foundation for financial stability and our ability to act. Without profitability, we cannot invest, innovate, or grow sustainably. Our corporate objective number two is innovation. This means we are focusing on the benefits and impact of our innovations. What matters is that we develop ideas that create real value for our customers and help us differentiate ourselves from the competition. The corporate objective number three is connectivity.
Our goal is to achieve profitable growth through systems business, digital services, and recurring business. Our corporate objectives define the priorities for Dräger's long-term development. We measure progress in all three areas through specific KPIs. For profitability, we set explicit financial targets that define the performance we aim to achieve. Innovation and connectivity focus on strengthening our competitive position and developing our business model, where we set strategic targets for several years. Also, starting in 2027, next year, the variable compensation of the Executive Board will be fully linked to the achievement of all three corporate objectives, and the variable compensation of the senior executive will be largely linked to these objectives. This directly links the goals that secure our future to the actions and responsibilities of our management. I will come back to this topic in my closing remarks.
We will report on our progress in achieving the first corporate objective, profitability, within our regular financial communication. The exact quantification of the underlying KPIs for corporate objective two and three is either still being defined or is not suitable for external communication for competitive reasons. We will publish an indexed value for each of these corporate objectives in our remuneration report, Vergütungsbericht. You will be able to track our progress. Let's take a closer look at the corporate objective number one, profitability. For many years, Dräger fell short of sufficient profitability and profitable growth. The loss in 2022 made the need for change very clear. We have therefore begun to realign the company and shift our priorities from increasing revenue to increasing earnings.
Profitability first is the redefined objective number one, and it's necessary prerequisite for financial stability and independence, investments, employee motivation, risk resilience, and capital market viability. Overall, profitability is essential for Dräger's successful longevity as a company that controls its own future. What does that mean for us? We increase our profitability by using our entrepreneurial flexibility to seize opportunities as they arise, while at the same time continuously strengthening our margins through price defense and cost discipline. The focus remains on aligning our activities even more closely with our customers' needs and consistently implementing our initiatives. Unprofitable activities will either be adjusted or discontinued. We can only become more profitable in the long term if we all do our part and we keep profitability in mind across all our activities. We measure our success in achieving corporate objective number one by EBIT margin, free cash flow, and DVA.
To remain financially sustainable over the long term, we must return to an EBIT margin of above 10%. This is a challenge we are tackling step by step. Since 2023, we have set and achieved the goal to continuously increase our EBIT, and our Ambition 2030 is a clear commitment to continue on this path. Profits must also translate into cash inflows and to preserve our long-term financial resilience and freedom to act. A high cash conversion rate that is consistent conversion of earnings into free cash flow is therefore just as much part of our ambition as profitability itself. DVA measures whether the returns we generate cover our cost of capital and create value. The return on capital employed must exceed its cost. Our goal is a consistent positive DVA.
For 2030, we want to achieve a DVA of more than EUR 250 million, coming from around EUR 90 million in 2025. Let's move on to corporate objective number two, innovation. Technology for Life is our guiding principle. Technology stands for technological innovation and engineering excellence, which are deeply rooted in our DNA. We protect our ideas with patents and secure the resulting competitive advantage. This gives us freedom to operate profitably and sustainably over the long term. What does this mean for us? We develop innovative products with a world-class research and development team in close collaboration with customers around the globe. In parallel, we invest in commercial innovation to develop business models that meet the needs of our existing and future customers.
We also promote local innovation and value creation in the countries where we operate, particularly in services, project business, and add-on software by developing and producing customer-specific solutions where they are used. We measure our success in achieving corporate objective number two, innovation share, and by patent applications. The innovation share or the revenue share of new products and upgrades is an objective measure of how customers perceive our innovativeness. Innovation creates value only when our customers adopt and use new products and solutions. Therefore, we must also successfully establish them in the market. Our goal is a higher innovation share. Patent applications are an important indicator of our future innovative capacities. They show how well we succeed in transforming new ideas into protected intellectual property and developing long-term competitive advantage from them. Let's go to corporate objective number three.
Technological advancements offer new opportunities for connectivity and, as a result, benefits through systems that support decision-making and process automation. This opens new possibilities for innovative products, services, and business models. At the same time, competitors are entering our markets with low-cost products that are becoming increasingly interchangeable. Our customers, too, are facing growing competitiveness and cost pressure. We are well-positioned to meet these challenges and take advantage of new opportunities. We differentiate ourselves through innovation, reliability, and customer focus. We have the reputation needed to successfully implement new solutions, and we have successfully built up our expertise in interoperability and system capabilities in recent years. Now it's time to consistently use these strengths. What does this mean for us? We are shifting the focus from the sale of individual products towards integrated system solutions.
Connectivity enables machines, devices, sensors, and software applications to communicate with one another on site or in the cloud. Interoperability ensures that these connected systems can seamlessly exchange and interpret data. By connecting our products to the cloud, we enable scalable remote access and data-driven services for assisted decision-making and ultimately automation. Service-oriented business models combine technological development and profitable growth with sustainable value creation. To support this shift, we will increasingly organize our business around customers' projects and contracts rather than on part numbers. We measure the success in achieving corporate objective number three by system net sales, connected customers and devices, and by annual recurring revenue. Revenue from connected products and systems is a measure of the evolution of our business model toward greater connectivity. It shows the extent to which we are able to connect components and integrated solutions and additional customer value.
The number of connected customers, in the middle here, is an important measure of connectivity as a prerequisite for future digital services and new business models. This will make service more efficient and improve safety, as updates and patches can be rolled out more quickly. Recurring revenue from software product license agreements, service contracts for our installed base, and services of all kinds, including the provision of hardware, is an important measure of our progress toward achieving this objective. Recurring revenue is an indicator of lasting customer relationships and make an important contribution to the sustainable development of our business model. For selected indicators, we do not disclose quantified targets, as doing so could reveal commercial sensitive information about our strategic plans. We provide transparency on our priorities and progress while protecting our competitive position. As I said, profitability is and will remain our most important goal.
In the past years, we have already proven that our turnaround in profitability is sustainable. Since 2023, we have seen a significant increase in earnings and profitability. This development is in line with our goal of increasing EBIT margin by an average of 1 percentage point every year. In 2025, the improvement was driven by strong operating business, in particular, despite missing one-off effects from 2024 and the U.S. tariffs in 2025 and the recession in China. That said, we believe that there still is upside potential for the future, and this brings me to our ambition for the next years. With our Ambition 2030, we would like to provide a clear view into the midterm future of Dräger and highlight the areas where we see potential and how we intend to continue growing through 2030. We start with the essentials. Oops. Quality and sustainability .
Because without these, there is no profitability and vice versa. So, sorry. Yes. To this. It was too early. But this Ambition 2030 is to achieve a stronger top-line growth, delivering higher profitability while maintaining our strong balance sheet. For 2030, we strive for an increase in net sales by around EUR 1 billion to around EUR 4.5 billion. Both divisions will contribute equally to this ambition. At the same time, our ambition is to increase our EBIT margin from currently 6.7% to a range of 10%-12%. We currently have a strong, healthy balance sheet, and this is important to keep our independence and flexibility. Our dividend policy to distribute at least 30% of net profit to shareholders is defined in a way to maintain this strength. In the next presentations, my board colleagues will explain how we are going to achieve these ambitions.
Now, we start with the essentials, quality and sustainability, because without these, there is no profitability and vice versa. That said, I hand over to Stefanie Hirsch.
Yeah, thank you, Stefan Dräger. Ladies and gentlemen, also from my side, a very warm welcome to our Capital Markets Day. Quality and sustainability highlight the responsibility we take. We take it every day and towards our customers and society. We set high standards for both, and we set our standards to deliver real economic value to our customers. Our many longstanding trusting customer relationships are proof of this. People entrust our products with their most valuable possession, their lives. Our products have to be reliable at all times, and Dräger devices must therefore meet the highest quality standards from development through production and delivery, from operation to servicing. Here, our Integrated Management System, our IMS, comes into play. Our IMS is a global system that applies to all Dräger companies worldwide, and we efficiently integrate processes across diverse stakeholder requirements, from regulations, standardization, and also economics.
We do not just manage growing complexity with it, we master it. We have this one Integrated Management System with zero redundancy, and it helps us ensure full compliance. Our guiding principle, quality drives value, reflects our focus on maximum value creation using this system, and it is across the entire process chain. The mature risk-based audit program we apply for the IMS with group-wide coverage ensures that compliance and continuous improvement apply. We have diverse quality control loops integrated worldwide into our business processes, including R&D and production, to drive continuous improvement. We manage our external audits and inspections with a longstanding track record, and this success secures our certifications, worldwide approvals, and business continuity. Ladies and gentlemen, we are, of course, aware that as a global company, we leave a footprint. At the same time, we are convinced that our positive impact outweighs the negative.
On the one hand, and this is what you see on the right side here, our medical technology improves healthcare. Our safety technology enhances workplace safety around the world. Our products protect, support, and save lives. Our purpose, Technology for Life, makes us an attractive employer, and in addition, we make a positive contribution to local and global gross domestic product. On the other hand, if we follow the illustration clockwise, we cannot rule out that human rights and environmental risks are existing in our supply chains, just as there is a risk of workplace accidents and potentially unequal treatment for our more than 16,000 employees. Furthermore, as a manufacturing company, we contribute to climate change, and we require resources for our products that are not yet fully recycled into a closed-loop material cycle.
We address those impacts, though, and it is through our sustainability strategy, because we are aware of our responsibility and want to make our contribution to this world and to the future. We are also convinced that sustainability goes hand-in-hand with profitability, and that this can create opportunities for us. Without ignoring the negative impacts on people and environment, we therefore say, "We love our footprint." Within our sustainability strategy, we focus on three areas: environment and society, customers and products, and company and employees. We aim to achieve continuous improvement in all of these areas. Let me now explain our actions, targets, and achievements, and how we can contribute to our Ambition 2030. In the field of environment and society, we aim to achieve net zero by 2045 and promote sustainable procurement.
For our products, we are working to reduce the product carbon footprint and develop products according to our eco-design criteria. We lower both product and transport packaging. In regard to employees, our priorities include achieving a Lost Time Incident Rate below 4.0 and advancing our Vision Zero program through training, expanding health-promoting initiatives. We also want to increase the share of women in leadership positions to 30% by 2035. In addition, our goal is to further develop our training programs. Reaching these targets should contribute to creating sustainable value, and therefore realizing our Ambition 2030. Out of all targets, decarbonization remains the most important one. For us, climate protection is more than just an obligation. It guides our actions and opens up new opportunities for sustainable growth. That is why we are aiming to achieve net zero by 2045.
Today, I am delighted to share with you an important milestone on our journey towards decarbonization. We adopted our climate transition plan and submitted our commitment to the Science Based Targets initiative. By making the SBTi commitment, we are pledging to science-based climate targets, while at the same time, our climate transition plan provides us with clear guidance for the coming years. How far now have we come in reaching our goals? In 2025, we reduced emissions from buildings and our vehicle fleet by 13% compared with previous years, while increasing the share of fully electric vehicles by 8%. Building on this progress, the measures we have defined will support our target of reducing Scope one and Scope two emissions by 30% by 2030 compared to our base year, 2024. Another milestone was the launch of our Circular One flagship project for customers.
This is an initiative to develop a sustainability showcase focused on decarbonization and circular economy. An interdisciplinary team of Dräger colleagues from product management, engineering, user experience, and sustainability is working to explore what a more sustainable future-proof product could look like. The project aims to bring circular thinking into product development, identify opportunities to reduce product-level emissions, rethink materials from the start, and establish better design principles. We help, on the other hand, our hospital customers to reduce their environmental footprint through more sustainable product solutions. For example, this includes anesthetic gas emissions through minimal and low-flow anesthesia, minimizing packaging and transport-related waste, and developing circular solutions that return selected medical plastics to the material cycle. Last but not least, we made further progress in improving management diversity and workplace safety. The share of women in leadership positions rose to 26.9% in 2025.
All of these achievements not only make us more sustainable, they also strengthen our resilience. Sustainability for us means mitigating risk. It creates value, improves cost efficiency, and maintains access to capital. We reduce risk through concrete and ongoing measures, and some I would like to share. Our supply chain is systematically managed and audited. In 2025 alone, we conducted 118 audits. This lowers dependency on single sources and reduces disruption risk. In addition, we have developed the climate transition plan I mentioned, setting out clear pathways to decarbonize our operations and to address evolving regulatory requirements. On the value side, we are designing products with eco-design principles for many years already and track the product carbon footprint, which increasingly matters to, let us say, hospital and industrial customers. Sustainability is becoming a purchasing criterion in our markets, supporting differentiation, pricing, and also quality.
Our Vision Zero safety culture is reducing our work-related injuries and reflects a broader commitment to workforce performance and retention, which in itself is a driver for our long-term value. On cost efficiency, we have made concrete progress. Our German sites have been ISO 50001 certified since 2025, and this provides a systematic framework for improving energy efficiency and thereby reducing energy-related cost. Circularity can help reduce our exposure to volatile raw material markets and improve cost predictability over time. Our target to reduce Scope one and Scope two emissions by 30% by 2030 is supported by measures such as energy efficiency improvements, renewable electricity, and fleet electrification. This can also help us to reduce our long-term exposure to energy cost and price volatility. Finally, on access to capital, our sustainability report is CSRD-compliant and externally audited, and this gives verified comparable data.
We are also externally rated, for example, by EcoVadis, which supports investor and lender confidence. Ladies and gentlemen, continuous external benchmarking is important for us. It is an important part on how we assess and advance our sustainability performance, and our performance is therefore reviewed annually by renowned rating agencies. In 2026, ISS once again awarded us Prime Label, placing us among the top performers in Health Care Equipment & S uppliers sector. We also retained our A rating from MSCI, while Sustainalytics classified our ESG risk as medium. This placed us among the top 30% of medical technology companies. In the already mentioned EcoVadis assessment, we scored 73 of 100 points in 2025 and are therefore ranked among the top 15% of companies evaluated. In addition, the Carbon Disclosure Project confirmed our C rating. Overall, very solid ratings that encourage us to continuously improve.
Thank you, and I would now like to hand over to Toni Schrofner for the medical strategy.
Thank you, Stefanie. Also, a very good morning, ladies and gentlemen, and a warm welcome also from my side to our first Capital Markets Day. I am Toni Schrofner, and together with my colleague Reiner Piske, I will take you through the medical strategy in the next roughly 40 minutes. We will outline our key priorities, the opportunities as we see it, and also explain how we have put already our strategy into action. Our mission, our direction in the medical vision is just simplified in three words: improving acute care. This mission statement is carrying following two key messages. We will, of course, continue and focus on the area of healthcare where the lives and the survival of very critically ill patients depends on highly specialized solutions, technologies, that is whether in the OR, emergency room, intensive care, or neonatal area.
This mission has remained unchanged since the development of the world's first anesthesia and the world's first time-controlled ventilator roughly 120 years ago. The success of our very close collaboration with clinicians and researchers over this long period of time is remarkable and also very beneficial for both of us. As an example, the number of anesthesia-related death today stands approximately at five per million. That is quite an achievement which we as Dräger has contributed a lot through all this continuous innovation in patient safety over this long period of time. Let's have a look, also in terms of how do we see and how is this success reflected in our presence, now today's presence in the medical division for our Technology for Life around the globe.
Just here illustrating with our very large installed base on anesthesia machines, we support clinicians in more than 50 million procedures per year to adequately put their patients to sleep, and even more important, to safely wake them up again. Our ventilators helps over 5 million patients annually to overcome the critical time, especially in their intensive care treatment. A good 500,000 premature babies are cared for in a Dräger incubator to be able to give them a very good start in life and also the best possible health for that situation. The second part of that mission statement is our ambition to improve acute care. The question, of course, is how can we further improve acute care by what I have just said before in these critical areas?
If we look at the current trends in the healthcare sector, and especially in particular in the acute care area, we see quite some conflicting developments. What do I mean by that? I'm starting on the left upper corner for you. As a result of the demographic change, the number of elderly patients continues to rise. These patients, who often suffer from multiple conditions, are making treatment even more increasingly complex. However, the growing number of new technologies, drugs, treatment methods is also contributing to the complexity of patient care. This rising complexity in both areas stands in direct contrast to the growing shortage of qualified staff in acute care. In addition, rising costs in hospitals are playing enormous pressure on the clinical staff.
Improving care, therefore, from our point of view, requires technologies and services that contribute to more therapy assistance and, if possible, also the automation of clinical processes, workflows, and therapeutic procedures. Have a look, if I just explain here the direction in our vision, in our focus on acute care, this is still based on a solid continuous market growth. How do we see that? The total accessible market for us is approximately EUR 13 billion. One-third of the market is represented by life support systems and workplace infrastructure solutions, which is more on the left upper side here, and scoring moderately, from our point of view, at roughly 3%, which can be explained that we have a very high market maturity and quite long product life cycle.
On the other hand, patient monitoring and bedside IT account for another third of our market, but are growing significantly faster in the bandwidth of 7%-10%. Finally, on the lower end of the charts, the installed base of our medical devices ensures a continuous stable business with our accessories and consumables, as well as a wide range of technical and digital services. When we look at our today's revenue distribution and our today's share, this leads us to a weighted CAGR of around 2.4, 2.3 percentage points because of the today's revenue distribution. If you have a simplified, a quick look to how do we see the competitive landscape in the areas of anesthesia, ventilation, infant warming, and workplace infrastructure products, we have established clearly an expanding and leading position over many decades.
While some players have withdrawn from the market, for example, in critical care ventilation, we will expand our market leadership in these areas through continuous innovations. However, the strategic focus is on expanding our business in patient monitoring, which is the basis for development and marketing of digital applications and for therapy assistance and automation. We have recently achieved some important milestones in patient monitoring, which I will explain in more detail in a moment. As Stefan Dräger has already explained, it is not only about sales growth, market shares, it is also about securing our leading market position, but primarily about increasing our profitability. For that, for us, for the medical division, we have defined four strategic levers to achieve this important number one goal. From the left to the right, the transformation from a medical device manufacturer to a solution provider in acute care.
Number two, our today's and even faster growth in the very profitable areas of our recurring business, our accessories and service. Number three, refocusing on those global markets which offer high profitability, namely in the U.S., but also in Asia- Pacific. Last but not least, implementation of measures to increase our efficiency across the entire value chain. Let me start with the number one. In the following, I will explain, of course, a little bit more in depth what do we mean by that. I am starting with the first lever, becoming a solution provider in acute care. As mentioned already before, what you can see here, it is a real life of an ICU. It is not just something for here, for the team, it is a real-life picture. As mentioned before, this increasing complexity is one of the greatest challenges in acute care.
This complexity results not only from the increasing number and diversity of different medical devices and manufacturers, it also has the complexity of different medications and clinical guidelines. But also very important from challenging processing of information to assess a clinical situation and derive out of that the right therapy option. To relieve also clinical staff of a very heavy cognitive overload, we are investing into innovative solutions that support clinical decision-making by consolidating and processing data from various sources. The prerequisite for this connectivity of medical devices is, of course, to be able to play an interoperable system with access to all relevant data. This transformation from a medical device manufacturer, from a pure device manufacturer to a provider of clinical systems, is a process that we have began many years ago and which we are continuously advancing through the development and implementation of new technologies.
In the 1990s, roughly, we brought already the first data connections between ventilators or anesthesia machines or patient monitors. By the early 2000s, we were already able to connect these devices to hospital IT systems and were also able to implement remote services. Since the very beginning, Dräger has been the driving force behind the development and introduction of an international standard for open communication between medical devices. This new standard, for many of you already well known as SDC stands for Service-oriented Device Connectivity, enables data to be exchanged between different medical devices, but also very importantly, securely, reliable, and bidirectionally in a very high medical-grade data quality. This forms the basis for the development of software applications for clinical decision support or therapy automation. Secure access to high-resolution clinical data is also a prerequisite for a proper use of artificial intelligence.
In some European Union-funded projects, we are working together with very well-known university hospitals, other medical technology companies, and innovative startups on data-driven applications for patient individualized care, and also on algorithms for the early prediction of patient suffering. The foundation, I mentioned it already, for the implementation and, of course, also of commercialization of digital solutions is our global market leadership in life support systems. We are well known in that on the left upper corner. But these are not longer simply standalone devices. This has to be and will be connected and already connected to interoperable systems. We use the new standard, I just mentioned it, SDC, to drive also the paradigm shift in patient monitoring. From a very today's device-centric architecture to an open network ecosystem.
We are combining life support systems, patient monitoring, and data into a very wide range of cutting-edge digital solutions. This creates value for our customers and offers us a strong differentiation from our competition. An example of that we will show you later in the showcase in our design center, the Silent ICU, the Silent Care Package, where we also have different partners implemented, integrated. Just brand new, and this is really not because of the Capital Markets Day, it was just happening two days ago, on MEDICA, Dräger and Sibel Health. Here I have to mention that Sibel Health is a startup in Chicago with a very high-tech, very innovative, advanced, let's say, wireless connected patient monitoring in terms of sensor. We are partnering with them especially for being able to continuously monitor patients on the general ward. Here, I am not talking about the ICU.
Why is this important? Because when patients move from the ICU, they are usually then not longer really monitored. Of course not, because the thinking behind is it is not longer risky, but there is still a risk. To be able to really also monitor vital signs in a general ward, usually today are checked by set of intervals, spot checking, as we called it. This is something where we can together with our Sibel Health partner, being able to also show ready and implement, especially in the Scandinavian area, wireless monitoring platform together with us, which continuously track vital signs, including heart rate, the classical ones, respiratory rate, oxygen saturation, through very nicely soft skin-mounted sensors. Also, this kind of new, very brand new products, I will show it in later in our showcase in the design center.
Just because it was really pretty new, we said we have to show it also here using the opportunity. Moving back to my flow from what I have said before, in the recent years, we have already developed a lot of those applications and launched numerous such of these digital applications. Together with our industry partners, here I like to highlight B. Braun and Ascom, we have created a system for secure distribution, very secure distribution of alarms to mobile devices and central dashboards, which means that the acoustic alarm at the patient's bedside can be continuously muted. This makes a difference and a very significant contribution by reducing noise pollution in the intensive care unit and allows us also to faster response on the very critical events, because roughly 80% of the events of the alarms in an ICU are not really critically relevant.
Here we are also proud, we are very proud to show you here, just three weeks ago, we have installed the first installation of our very unique Silent ICU solution. We went live at St Andrew's War Memorial Hospital in Brisbane, Australia. This important milestone could be only achieved thanks to a very close cooperation of Dräger and Ascom with the Critical Care Research Group, a team of clinical researchers in Queensland, led by Professor John Fraser, who is quite a well-known person in this area, who strive to improve the experience and outcomes of critical care patient. The silent alarm features, and this also important, was a deciding factor in winning the contract for patient monitors in the intensive care unit and was allowing us to replace the previous monitoring supplier and was also successfully defending our ventilator families against the competition.
Let me come back what I have started for with the Silent Care Package to our total digital solutions portfolio. Here on the second block, in addition to application-based and device-to-device interoperability, which I have shown before, we also provide technologies based on data distribution, such as real-time data streaming and enable clinical apps for remote access or for therapy data analytics beyond the bedside. On the third block, the standardized open network also allows us to integrate data at the point of care. So we bring together the monitoring and therapy control in one central software application to present information in the clinical context, and also reliably support decisions through integrated clinical protocols. On the fourth block, we are generating also cost and asset transparency with apps and dashboards that support the hospital in optimizing resources and processes.
The networking of the devices also enables remote maintenance of each individual product, including the distribution of new software updates remotely. Last but not least, on the fifth block here, we provide an open state-of-the-art platform to distribute high-quality data for, I already mentioned that, AI-based clinical research and development so that uninterrupted safe operations is guaranteed. Let me come back, because this is also a topic which, of course, most of you are raising in many times, to our patient monitoring situation. The reasons why we see us now in a very good position to regain market shares. On the first wave here, on the first part of the chart, on the last couple of years, we built a very solid foundation. What do I mean by that? We completed our enterprise monitoring portfolio in the basic segment with our Vista family.
I come to that on the next slide. We reached also critical mass with our Dräger Open Network ecosystem, and we received, very important for the U.S., of course, the 510(k) clearance for our infinity monitoring system for the U.S. The infinity monitoring system, which I can illustrate here on the next slide, here on the right part of the chart, is illustrating, and it is also showing that this integration of the Infinity Care portfolio into our SDC-based open network ecosystem will further strengthen our position and share in developed market, high developed markets. It is also important to know that our Infinity Care System is fully developed, sourced, and produced in the U.S., and also relevant for, let's say, the very important biggest market, single market, the U.S., of course.
On the right side, you see while we have the introduction, continuous advancement of our Vista patient monitoring portfolio, we provide a very comprehensive, and at the same time, a very affordable enterprise monitoring system with a strong focus on the upper basic markets. This portfolio we develop and produce and source with our long-term, longstanding partner, Edan Instruments. It is a family-owned on the Shenzhen stock market, a place company where we have longtime cooperation, and the total portfolio out of that we do in a partnership with them. These both areas, we have contributed and, let's say, solved a lot issues in the past. If I move now to the second phase, so now and 2027 onwards, we clearly see that we can move forward now with accelerating our global presence because we have now a very suitable, a very competitive portfolio.
Again, the 510(k) rule for the entire Infinity system, and also relevant, that based on the 510(k) rule of the Infinity system, we were also able to lift the warning letter. This means also that we can fully focus now on re-entering the U.S. market, which we could not before. Moreover, the solved FDA topics free capacity, we would not underestimate that this, of course, also quite consuming a lot of capacity, especially in engineering. This, let's say, free capacity now, we can focus again for really high-value innovations, making even our monitoring offering today and in the coming years much more competitive. Reference sites such as the War Memorial Hospital, I just showed it before in a slide in Brisbane here, with the first ICU installation, will also support in the high-developed markets also our monitoring business here.
In the third phase, we will significantly scale up our monitoring business. Here, the SDC standard is more and more established itself as the leading standard in acute care in the coming years. We will be able to leverage, as we see as our head start in our implementation across the entire portfolio, to differentiate ourselves with interoperable solutions. The increasing number of software applications and the change towards subscription models will also grow our recurring revenues and thus expand our margins even further. By now, showing a lot, I will hand over now to my colleague Reiner Piske, who will introduce our second and third lever. Rainer, please.
Thank you, Toni. Also a warm welcome from my side to everyone here in the room and also on the screens to our Capital Markets Day. We highly appreciate the opportunity to get this morning into a dialogue with you. Grow recurring revenues. Like in many other industries, the business with accessories, consumables, and services contributes already today significantly to the overall medical business. It provides or it is a strong and attractive business in terms of profitability, resilience, and cash generation. As our installed base grows, also in the coming years, this business creates for us highly recurring, predictable revenues with attractive margins. Our opportunity is simple, to capture value for every device and solution we install over the entire lifetime.
We have the customer relationships, and we have also the ability, and also we have a strong service footprint to exactly do that. Our portfolio of hospital consumables and accessories ranges from highly specialized, dedicated consumables and accessories through everyday consumables. First, we have dedicated accessories as an essential part of our systems. They ensure the clinical performance, the compliance, the regulatory compliance, and also the patient safety. Secondly, we offer more generic consumables, such as filters, masks, and breathing circuits. Thirdly, we offer customized pre-assembled kits with which we also improve the workflow in our customers' facilities and save here valuable time. If we talk about this business, I mean, customers and hospitals do not buy only equipment. They buy reliability, they buy uptime, and they buy peace of mind.
Patients' life depend on our technology in the operating room, in intensive care, and in neonatal care. When critical equipment is needed, then failure is simply not an option. That's why our service organization is such a strategic asset for us. With more than 2,000 service engineers in medical worldwide, we have an extensive partner network. We have here, we operate, I can say, one of the strongest service organizations in the whole industry. That means this is a clear differentiator today and an even greater opportunity for tomorrow. Our installed base of today already more than 1 million acute care devices worldwide is further growing. Every device we install creates the opportunity for services, consumables, and accessories over the whole lifetime. With this, we will be steadily increasing our share of recurring revenue in our business model.
Today already, hospitals, consumables, and services generate already more than EUR 700 million in the P&L in annual sales. However, we believe that the opportunity is even larger. That is why we continue to invest in dedicated sales force, in portfolio expansion, and also in service capabilities to unlock this potential. This is not a future initiative. This is already ongoing. Talking about service, we are equipping our service engineers with digital and remote capabilities that allow us to use already installed base insights. Here an example, device utilization analytics, for example, brings information on the device status already to our service engineers. They can use that information and prepare service more effectively, supported also by remote troubleshooting.
This helps also to improve the workflows and the effort which is needed in our customers once there is a failure and also in terms of maintenance. Thus, we provide the rapid response which is expected by our customers and the high service standards. This we do not with our local service networks globally, with our global service centers, remote services, and data-driven tools. Let me explain a bit more what we are doing in the regions and how we act from a go-to-market point of view in some of our most important regions. If we basically, why we differentiate this? The need for reliable acute care is possibly or probably universal. However, how reimbursement system work, how hospital technology is being purchased, and also the purchasing power varies actually a lot across the world.
Therefore, we continuously adapt also our footprint in the world, and we, as we see the best opportunities for sustainable growth and value creation. This disciplined allocation of our resources is also part of our strategy. Let's start with the U.S. The U.S. is the largest healthcare market in the world and a major growth opportunity for Dräger. We are present in the United States already for around 120 years, and nowadays , we have additionally to sales and service also a monitoring production facility. Our ambition in the U.S. is to increase our net sales by 4%-6% annually through 2030, and this although trade policies and the economic situation in recent years have made, for many industries, also ours, business in the U.S. more challenging.
However, we are building here on a very strong position which we have here in anesthesia, and expanding our life support business, dedicated consumable sales, and a greater service coverage will also help to achieve that growth. Toni mentioned patient monitoring. Patient monitoring provides here a clear additional growth sector. Following the 510(k) approval or clearance of our latest Infinity Acute Care System, we are now really in a position to compete more aggressively for monitoring opportunities, especially in hospitals where we have already good clinical relationships. To further accelerate our growth in the United States, we are currently reorganizing our sales organization in the U.S. around a dedicated business unit style leadership with a clear accountability by modality for growth, market share, and business development.
This combined with stronger clinical expertise and service and key account management in the IDNs and also handling the GPOs creates a more scalable platform for growth in the future for us in the United States. APAC also offers substantial opportunities for us with its growing population, its rapidly expanding economies, also the rising standard of living, which also evaluates or improves the standards in healthcare. However, in APAC, this calls more for country-specific or region-specific approach. Whilst in India and ASEAN, we see opportunities as healthcare capacity and access expand. We see ourselves in China with a focus on a more competing effectively in a country with quite some restrictions in terms of localization requirements and also the access to the market for all foreign companies in China, a restricted access.
Localization actually is central to our approach to have, on the one hand, market access and also a better price position. In China, Indonesia, and in India, we are aligning our footprints to local requirements. India is becoming the development and production hub for our upper basic portfolio, high-quality technology designed for more price-sensitive market. Localization and the expansion of our upper basic portfolio, of course, improves also our cost position, supporting actually profitable growth. In APAC, additional growth will come from hospital projects. Here we combine actually our ability for workplace infrastructure with the devices and solutions and also with consulting. Our commercial goal here is, of course, in such projects to get just a higher or to increase our share in project value. We have lots of turnkey projects in APAC, in different countries in APAC. This also offers an additional growth opportunity.
Europe remains our foundation. It is our largest region, the biggest profit contributor, and the showcase of many of our innovations. As hospitals across Europe are under increasing pressure for greater efficiency, productivity, and digital integration, our connected solutions actually address these needs. We will use our strong installed base also for fostering the recurring business with hospital consumables and accessories and our wide range of product and digital services. Our head start actually in the implementation of the o pen network system based on the standard SDC will also push our monitoring business in Europe. We believe, with our strong installed base, the leading service organization, the growing digital portfolio, and our deep customer relationships, we will not be only defending our position in Europe, we will be strengthening it. With that, I hand back to Toni Schrofner.
Thank you, Rainer, again. Let me move on now with the fourth lever, last but not least, how do we drive efficiency? We have three major areas. Here the first area, we have clearly, over the last past years, implemented a lot of measures to improve our gross margin across the portfolio. Lean operations service initiatives, we drive excellence in these areas and accelerate automation, will lead us to 2%-3% productivity gains every year. Our new competence center in India for the upper basic portfolio contributes to this as well. We have initiated early this year a purchasing excellence program where we are using material costs by qualifying alternative suppliers, doing redesigning parts components, and in addition to that, this will also allow us to make our supply chain more robust and mitigating the risk of shortage.
We are also successfully managing to compensate for the continuously rising costs and inflation, adapting our pricing, especially on our value selling for our solutions in the first area. A second one, a quite important one, a key element in our value chain, these are our research and development centers. In recent years, we have started already to expand and shifting more and more our footprint from west to east. What do I mean by that? We have acquired in the course of 2022, 2023, a company called Quadigi. We began already to transfer an increasingly large share of our software development to a very motivated, capable team of young and skilled engineers in Lithuania. Right now, in the course of 2026, 2027, we are talking about more than 200 software engineers, very skilled and very passionate, especially for this big, let us say, ongoing increase of software applications.
To broaden our upper basic portfolio, we continue to expand our R&D and operations in our new competence center in India here. Why I mention this, why is this so important? I will show you later also some impressions when we're moving to the design center, because I can also highlight that out of that Indian upper basic competence center, we are launching now, end of November 2026, the first fully developed, sourced, and manufactured anesthesia device on the lower end from our portfolio with a very competitive range of our cost position and also very competitive in terms of quality. Again, you will see some impressions later. The implementation of agile development and, of course, the increasing use of AI. We're using significantly already named here, especially AI coding agents like Claude Code for our software development.
We're also using AI for pre-validating our eSTAR submissions for FDA to really make sure that everything is in place. These two examples and a couple of more of them are expected to significantly also help us in gaining productivity in the next years. Another factor for efficiency and cost reduction is the ongoing migration of our large legacy product portfolio to a more modular, scalable system. One example here, we have already implemented the so-called unified software architecture, one vent for all the ventilators, all the ventilator product family, and also a limited number of hardware variants. This is also something which we strongly believe this helps us to build a very flexible and streamlined portfolio. On the third block, last but not least, we also have a couple of initiatives in our sales and service organization and in our administration processes.
The transformation from a very device product-oriented sales force to a more solution sales. We will also adapt, Rainer mentioned the example of the U.S., our sales structure and capabilities, shifting more to a focus towards C-level enterprise selling, and this will also help us in terms of gaining here additional market shares. We will leverage our portfolio from the recurring business with our consumer accessories by dedicated sales force. We have this already in place in the couple of years, but we will further expand that, and even more utilizing this with digital sales channels. This will also backed up by a couple of AI-supported automated back-office processes. It's another example. The regional service activities, Rainer mentioned that already. Finally, we've also identified potential in reducing our general administration expenses, both in the headquarters and in the regional hubs.
By all of that, we have the clear ambition that we grow our business in the next five years by EUR 500 million to reach the EUR 2.5 billion in 2030. At the same time, even more important, improving our bottom line performance step by step. This would lead us then to a range of 7%-9% in the course of 2030. Maybe some more on that. How do we achieve that, especially if I'm talking about the growth ambition, because the growth is quite significant. I mentioned that in the beginning, our sales, our today's sales weighted market growth is around 2%-2.5%. Our ambition is clearly to grow 2-3 percentage points faster than the market, and there are two main drivers, not only two, but two main drivers. This was already covered by the presentation.
Number one is the growing recurring revenue by effectively exploiting the installed base, which is a very attractive margin on that business. Then number two, becoming that more and more solution provider includes care with a system of interoperable products. By saying that, of course, we also keep on going with very attractive launches in our life support systems. Overall, this would lead us then in the bandwidth of 4%-5.5% per year. If I would sum it up, summarizing all what we have presented, Reiner and myself, our goal is clearly to grow faster than the market and to substantially improve our profitability. How do we do that? The number one solution recurring, I mentioned this now a couple of times, and in this business for our growth engines, we are ready, really ready to reclaim market share in patient monitoring.
On a regional view, U.S. and Asia- Pacific offer larger opportunities, what also Rainer covered. Last but not least, we systematically drive efficiency to improve the bottom line. So, on behalf now of the Executive Board, which was the end of my presentation, I have to thank you very much for your attention. Again, highly appreciated your participation, and also special thanks to everyone who helped us to host this meeting. Handing back now to Tom Fischler, how do we continue? Please, Tom.
Thank you, Toni. Thank you to all the speakers so far. We will now start our first Q&A session. If you have a question, it would be great if you just signal shortly and then wait until the microphone reaches you so that the online participants have a chance to understand the question. We have a first question here from Oliver.
Yeah, thanks very much. Two questions from my side. Firstly, on the kind of regions. Can you just specify what kind of growth assumption you have for China and this kind of 7%-9% growth for Asia- Pacific? Also for the U.S., the 5% growth assumption, can you just talk about the timeline of the growth acceleration? Because I guess bringing in monitoring takes a bit of time to really ramp up. Secondly, on the SDC that you talked about, can you just provide a bit of more color of the kind of commercialization potentially here? I mean, I guess Philips is now increasingly offering the kind of own standard, so what is really the difference that you bring to the market? The new data models you have here, is it a kind of direct competition to Philips' Capsule business? Thank you.
I think, Rainer, that is the first one on China is for you.
Yes, I am going to start. The mic is working. Basically, the growth in China is, compared to the other parts of the region, lower, the growth assumption. While we are expecting actually in India and ASEAN, for example, a higher growth rate. In China, due to the, let us say, more challenging environment, also in terms of market access, restrictions to market access, and the localization, the higher, let us say, requirements in terms of localization, which we are doing basically, we expect here basically in China a growth which is below that. Let us say more to about 3%, 4%, 5%, whilst we expect in other countries such as India a growth of more a double-digit one. All in the mixture, it will come up to the figure we have mentioned here as an overall estimated growth for APAC.
Your second question, for the U.S., what is the timing in terms of the growth expectations? We expect also that this will be accelerated. However, we expect already for next year in medical in the U.S. already a growth in the range which we have presented overall. It is not a hockey stick which we are expecting here towards the near-term future. This was my part for the regional part.
I think you had a third question regarding, it was more SDC-related, correct? As I have presented, as we see it, in the first run, we do not see that ecosystem as an additional independent commercialization source. We see it as a package. I will give an example on that. Memorial Hospital, I can even take the example Guy's and St Thomas' Hospital in U.K. As soon as the customer has experienced and seen the advantage of using that standard, we are able to really win then the deals, including our today's life support systems and monitoring. It is a combination. Immediately, if they have recognized this advantage, I stay with that example, Guy's and St Thomas' in London, which I did not show, there was a very tough race in terms of at the end, we and, of course, against a well-known competitor.
And what they did then, they decided, "Okay, I have understood this ecosystem on the long run, and we as a hospital like to transform also step by step our equipment." This helps us a lot to also get deals from today's life support monitoring ventilation system. This is, I think, one of the biggest levers we see also supporting, if you like to say, the classical modalities. On the long run, we see more opportunities with SDC because at the end, we are talking about a bidirectional functionality. We will be then able to maneuver, if I take the ICU again, on the bedside somewhere from remote. We can then put maneuver in place, which is today regulatory-wise not already in place.
This is also something what I mentioned in my presentation when you talk about the complexity which is rising, the staff shortage, which is helping them a lot. Last but not least, to not underestimate also the clinical outcome. This is today not already, let's say, put in place in terms of how do we deal with that from a reimbursement point of view. But the example of Australia, they put a lot of effort by noising, or this kind of noise reduction in the ICU, how can we also gain from a patient outcome point of view advantages on that one? A couple of things, multiple things, which we think is the benefit of using that standard. Yeah.
Thank you, Toni. Any other questions here from the room? Yes, please. Mark.
I have a question regarding your R&D expenditures going forward, because 10 years ago, you were announcing that you have a significant step up, which we all have seen in your numbers. I would like to know, is there in your guidance embedded a certain, let's say, normalization, or are you keep on going investing in R&D since you have also innovation as one of your targets? Thank you.
Medical, you are talking?
For medical, yes.
Yeah. Me again. As you said, we are spending significant amount of money in R&D the last couple of years, and we are now starting to also being able, because we are bringing a lot of new products to the market out of that, let us say, significant R&D engine in the next, let us say, from 2026, 2027, 2028. We are not talking about specific launches now, but what I can tell you, we will launch now in the course of early 2027, in the whole year, including early 2028, from an amount point of view, we have never launched so many products in that short period of time. All that big investment, which we are true, we have invested a lot, we are now starting because of bringing these products to the market to harvest. There is a second element.
We have also, of course, invested significantly in our ecosystem to be able to play that, let us say, role from a modality versus connectivity point of view. In the short term, these big investments we can utilize now, starting now, 2027, 2028, to really accelerate our growth with that attractive portfolio.
Maybe just to build on that, we will add some quantification on this on the group level this afternoon in the presentation of Gert-Hartwig.
Thank you.
Thank you.
Still a question here for the room. Then we will take a minute and take a question from the webcast. A question for Stefan Dräger. You stated that unprofitable areas will be reassessed. Which specific product lines or sub-segments are you thinking of?
Yeah, good question. Please understand we cannot disclose all the details of the areas that we have under review because that's in respect of the people and customers, suppliers affected. However, we can share quite some details from either things that we have as work in progress or already completed. We did share in the past that we sold off the business for fire and gas detection in Holland. That was for office and commercial buildings, but is not the typical Dräger application where we use our own products, like on oil rigs or refineries, where there is a hazardous environment. For this application, for, let's say, office and commercial buildings, that was a specialty in the Netherlands that was dilutive to the margin, so we sold this off to a new owner where it can prosper in a more suitable environment.
The other example, we also discontinued our business with what we call the MSI in Hagen in Germany. That was a company specialized on emission control and analysis from fossil fuel burning and furnaces. On a longer-term perspective, that would be a declining business and has not such a growth opportunities that we have typically in our markets where we have Technology for Life, that also found a better owner, is no longer part of the Dräger business. These effects, I can mention a third one. We discontinued the interlock business with ignition interlock for cars from offenders that violated the driving under the influence regulations in the United States. We no longer serve directly to the end customers in the United States. We do continue this business in other countries in the world.
Three examples of what we are no longer doing, and that can be named these, let's say, changes have a small effect on our top line, of course. It is reduced by these respective revenues associated with these three businesses. Toni already included in his presentation some areas where he's working on, say, making changes. Reassessment means not necessarily closing, but it can also mean that we relocate the production or we outsource this and work with partners and no longer do it ourselves, like that's the case largely with monitoring in the future. Toni included already some examples from Lithuania, from India, and from China, where we improve our profitability.
I think maybe Rainer Klug can also comment, because your presentation is only later, so I think it's the best if you include that later in your presentation, what your contributions are from the safety division.
Thank you, Stefan. A question here from the floor? Yes, please.
Looking at the medical division, we saw that your investments in Künstliche Intelligenz, so it is artificial intelligence, are increasing. The results we will see later. Now, we saw, for example, in the last quarter, the cost. Maybe you could share with us, looking the use of artificial intelligence, can you already see that, compared to your former plans maybe one year ago, that you see improvements in the timeline of the software releases that you plan? Maybe you can share a little bit of the impact of these investments. Thanks.
Thank you. Two questions, or two answers to the question. If we look at how do we use AI in the medical division, there are two elements. One is, how can we use already the AI in our therapeutic applications? How do we use it for clinical purpose? We come to that in a second with an example. There is a second element, what you are referring, do we already see efficiency gains from a software development point of view? Because if you talk about AI, it is really the focus on software development. What I can say, what we see, that the coding, the life cycles for really, let us say, looking into the software packages is going much faster already. We have initially, let us say, extensively started to use it in our software areas in Lithuania and Lübeck in the course of starting in some extensively.
In the first half, it was more tried out, yeah? Now it is more and more extensively professionalized. We see already the cycles, if you talk about coding, if you talk about how do we prepare our eSubmissions for the FDA. This run through is significantly faster, of course. We see this already, and we are quite convinced this will materialize sooner or later. Maybe not now yet, but it is definitely a ramp-up. The second part, I would answer like that. If I am talking about how do we use already AI from a clinical context point of view, there is a nice example, an application lung protection ventilation, which was already using data from the ventilator, combining it with patients to predict, or let us say, to forecast better from a lung protection point of view.
And here is also quite a clear example which we are already having in place to show that. Yeah. So, two different elements. Yeah.
Thank you, Toni. Trying to somehow stay in time schedule, let's maybe wrap it up with one final question. We still have two further Q&A sessions coming. If there is a further question here in the room, then please, Oliver.
Yeah, thanks so much. Three quick follow-ups. One on pricing in medical. How confident is your sales force that they really can push through premium pricing in the market, which is still quite competitive? Secondly, on this recurring revenues, can you just give us a flavor in terms of how superior is the growth here and some tangible examples what is going to accelerate this recurring revenues growth apart from the installed base? Then thirdly, I mean, you talked about this low-cost country move. You talked about India and Lithuania. Can you just give us any flavor what percentage of costs are moving towards low-cost countries from Western Europe so far?
You start?
Sorry, Tom, for having three questions.
Starting with pricing. The price enforcement, we have actually improved here a lot. However, after the inflation in many countries goes down, the enforcement of higher prices is not on the level of 2023. However, we are able in both medical and safety to definitely get our own cost increase covered. Also towards the future. And we are confident that also in the coming years, at least this goal will be achieved. If not, it is even contributing to more profitability, that we achieve here price increases. Of course, I have to say, it is different in different parts of the world. Giving you an example or giving this variety, for example, in China, it is not possible currently to really reinforce price increases.
Here we have another environment, a demanding environment, and here we want to actually come back to growth a little bit and actually get here more or other challenges solved with the strong competition we have also from Mindray here in that area. Recurring business, it is on the one hand the installed base, which I have referred to. On the other hand, it is also more dedicated staff and also leveraging on a service network also with other providers in countries in which we have geographical challenges to expand that part. Then I want to give also a third lever, which is the digital services.
This digital services is really an important lever because it helps also to address the challenges of the hospitals who need to improve their own efficiency and their own productivity and digital services. To give you an example, of the university clinic in Stuttgart, where we sold actually what we call OR Companion and also the connectivity or the connection of our devices via the service gateway. This actually improves the connected devices. In the past, the clinicians needed actually to, if there is something going wrong in the operating room, they need to issue then first a repair note and so forth. This is all automated now. With the OR Companion, we can actually ensure that the respective tests which the, again, the anesthesia staff needed to do every morning, this is done automatically. It improves basically the workflow, saves a lot of time.
With the connection to us, we can even remotely, some failures we can remotely solve. It is also important, this part is also important to leverage our recurring business and service sales, just as an example.
The question was more this, what about the impact, the cost shift if you talk about footprint, so from west to east, Lithuania and India. On the overlaying target, we clearly said there are different reasons for that. We like to use that ramp-up in those, of course, very competitive areas by not further growing in high expensive areas. That was one first element. There was a second element, you can get to Lithuania, we have more and more software applications and software products, so we need that speed and that power from that kind of area. We are talking about quite significant critical mass of software engineers, but also in terms of using that sites for even giving them the full authority of lifecycle engineering activities.
This means then that focusing then the area here or in the U.S., where the real innovative products and outsourcing, if you like to say, the lifecycle part. In India, it is a little bit different because the focus in India was clearly India in terms of setting it up for the basic India first. The products right now, or the product which I show you later, which we are launching November, has three different, let us say, time windows. India first. If they are successful in the course of early 2027, see that, we are using that portfolio out of India for Asia- Pacific. Then the third way, if you are using this upper basic portfolio globally means for that markets who are asking for that competitive, let us say, portfolio, like Africa, like South America, like South Europe.
Different approaches, but clearly benefit for us in the total, let us say, margin profitability improvements.
Okay, thank you. Just a really quick last one here from the online audience. A question on if we would consider unifying the common and the preferred share classes to boost liquidity and simplify the capital structure. Stefan.
Yeah, indeed, that's a quick one. It's not a new one, though. We are aware of the great potential for increasing liquidity and simplifying the structure, so that is quite tempting. However, we will resist and not do it, because then we will probably limit the leeway to maintain our independence and control for one generation ahead, and that's not enough. We think in more generations and thinking further ahead, we are very happy with the current structure.
Thank you for the straightforward answer. Now we would conclude this Q&A session and have a short coffee break. We would resume with the deep dive into the safety division at quarter after 12. Thank you. Welcome back. We continue with the second block and our second deep dive into the business, the ambition of the safety. Rainer Klug.
Yeah, thank you, Tom. Is my mic on? Yeah, so you can hear me, I guess. Yeah. Warm welcome also from my side. Hope you had a relaxing coffee break, before we enter into the safety business. I'm Rainer Klug. I'm responsible for the safety business, and I will do that explanation presentation together with my colleague, Reiner Piske later on, for sales and service. What we have prepared for you is that we combine the future with a little review back to the year 2022. As you already have heard from Stefan Dräger in the initial part, that was a tough time, but that triggered something also for the safety. That is clear to us. Before I start into some of our elements of our figures, I would explain to you a little bit what is Dräger Safety and for what stands Dräger Safety.
What is it what we do? At least we protect health and we improve safety principles, and that is what we do for three elements. It is workforces, safe working environments, it is industrial assets, that the assets are protected and damage can be avoided. Damage on industrial assets can harm environment, and that is very important to us. That means we have that third field, environmental protection as well. Our customers are working on their own goals. We have heard already about a Vision Zero systematic. That is the vision having no worker accidents, and that is what we do to support it and to bring or work out with them together the right principles with the right technology in very harsh, typically in very harsh environments. That is what we do in our safety business. These three elements are essential.
Coming into the time, that little review here, when we had to transform the safety business, because there was a time in the year 2022 where we had at least zero profitability. Usually, I would say you see that column, but you cannot see there was none. That was really the challenge. It was the time when the supply chains has been disrupted significantly from external shocks, and we were suffering from that as well. Usually, I would say if a company is robust enough, if a business is robust enough, it would have harmed us, but not that much. We came out of a history where we had typically around 5% EBIT. That external shock could not be digested at the time.
To be honest, it was not a technical shock, it was also a shock for us that we were not able to react properly in one year. But it triggered something. It triggered definitely that we have to run into a turnaround systematic, and the turnaround systematic was scheduled and planned already in the year 2022. The execution started end of 2022, and it ended up in a, yeah, we can say it was a successful turnaround, so that we could achieve 9% EBIT at the time. At the same time, we used the dynamic in our teams. We have huge teams. They all love Technology for Life, and we could make use of the dynamic at the time to build up on a strategy, a transformation program, a comprehensive transformation program, which at least we are standing on today, and we will talk about 2030 as well.
This comprehensive program carries us with a dedicated strategic deployment plan through the time, and you see that 2024 and 2025 has moved up as well. We have also, I would say, a revenue CAGR growth established, which is in the ballpark the same than later on up to 2030. That I will show you now why I bring that early, because the bridging the years, which we see here, shows the gap between 2025 and 2030 just by design of our chart, of my chart here. But Reiner Piske and myself, we would like to explain and introduce to you what is the background, why we are confident to move that business up to EUR 2 billion revenue and the EBIT ratio of 14%-16% over the next years.
So, and that starts what we stand for, as I said, harsh environments, robust technology with our technology. What we sell is an offering which is dominated by, I would say, hardware portfolio so far, and that plays in attractive markets. Our position there is, if we take the three very relevant ones, it's the gas detection, the breathing protection, and it's the impairment checks. If we take these three into account, we can say that among these three, we are in the top three players in the world. On the other side, we have these, I would say, wide variety of industrial segments where we are in. So that's kind of matrix where we play, where is the industrial segment. Now it comes the perspective to the portfolio, how to handle this portfolio.
We have here just a very little number of portfolio elements shown, but Dräger has 22,000, or Dräger Safety, sorry, Dräger Safety has 22,000 active sales articles. Is that necessary? We believe it is. It's very similar in our competition environment as well. But the core behind it, and we have heard already something about it today, what is the overarching core of this company? That is the knowledge of sensing gases, having a deep-rooted understanding of respiratory protection or respiratory in general, and that's what we keep as core technology, and we build up on the portfolio into these two, these very different application fields and industrial segment fields. This together with some of the global trends we see actually gives us a wide and a strong base for further growth.
We take some of the top trends actually, where we can apply this entire portfolio and the core technology. That gives us the perspective that we operate in very healthy market. I can have the best diesel injector, but it may doesn't help me because the market is actually not a healthy market. So we are operating in healthy market, and I think that's an important takeaway. These strong global trends provides us the growth spaces. One element, transformation of global energy supply, we called it. We started four years ago to really approach and push into the clean tech environment. But the clean tech environment is depending on, I would say, governmental, I would say, frameworks. These frameworks are moving. But what happened?
Even if a green hydrogen that does not materialize as fast as thought, bridging technology is still there, because the demand for energy does not go away, so it stays. If an LNG terminal in the Baltic Sea or in the North Sea has to be built, it has to be built under compliance regulations and has to be built secure. For us as a gas detection company, it's very important. Then we go in the early trends, carbon, capture, utilization, storage. All this has to be and will be regulated in terms of secure working environment. That's what's coming up on these, I would say, infrastructure models. That will be combined with digitalization and automation. There's a good reason why we have that in our corporate objectives.
This comes together under a network systematic, goes into cloud-based systematics to build up to have the data transparency and to steer these systems. I come to this later because that moves over then, can move over also into managed service models. Increasing safety regulations. Here in, I would say, center of Europe, we have very strict, also or same in the U.S., we have very strict, I would say, protection environmental regulations, and these regulations are increasing in other areas of the world as well. So if we go into some of the emerging markets, in Asia- Pacific or Central South America, that is moving up. So the demand for safety, workers' safety, workers' health is increasing. Then for sure, yeah, okay, I would say, on one side, the most depressive one, on the other side, opening up business opportunities is the geopolitical conflicts we see.
We come to the defense business in some minutes. Give you an insight about our market. The market, as we see the market, has a size of around EUR 11 billion. That is our addressable market we are working in, and it's a growing market with 4% roughly. That's assembled out of different elements because our technology through that fragmented market environment is always very differentiated. So that means we have differentiated market access, we have differentiated portfolio to make use into these elements and to, I would say, push individual in these markets. So, I think, you see here, if I take only one out, engineered breathing protection systems. That is a strong growing market with 6%, and that's an element where defense comes into the game, because that is protective equipment for defense as well. Now let me go into some of the targeted focus markets.
What is that, what we target there? We have a little overview prepared, just four important pillars. Grow and profitability, we have put a little bit the arrows in here. Defense, for sure, in the center of the slide, is very strong. The other ones, strong as well. I would say defense is extra strong. Why is it not only grows and why we consider that together with the profitability in the individual areas? The profitability depends on the product groups we're selling. All these segments are using the most profitable product groups we have in Dräger, in Dräger Safety, sorry. That's the key element of it. So we can scale up, we can leverage, and that's the idea behind it, why we're pushing into these, because our technology with the highest profit fits the best. Growth area, fire service sales in the U.S.
The U.S. is the biggest individual fire service market we have on the globe. For sure, that is dominated from U.S.-based companies. Luckily, we are not shy to enter into the competition with them. That market is characterized through an approval cycle. The regulation in the U.S. has the NFPA approval, as shown here on that slide on the left, second bullet. That approval cycle is coming up every 10 years. That opens the reprocurement for the fire services. So they enter into that cycle. That cycle started recently. We have developed over several years the right product to be excellent positioned in this cycle now. That's the Dräger AirBoss. That's a system which is made for America. Yeah, I'm a German, I'm a European engineer, so, and we typically love to develop European products, and then we derivate this into other regions.
That we skipped here. We dedicated, developed a product for the American market with the input from American firefighters. What we see so far, it is very much appreciated. The growth element into that is the last bullet point here. Our market position actually is the number three, and we want to move into number two. Behind that, as I said in the beginning, there is a strategic plan, a deployment systematic. There are numbers behind this. What does it mean to us, and how does that feed our growth paths? Just to give you a little, maybe an example. The first bullet says, American-based competition. We are actually in the trial, and then Fire Department New York. Fire Department New York is the biggest fire department in the world. Nothing is bigger. It was dominated by one of our left competitors over 60 years.
60 years, Fire Department New York had this company as their supplier. We could make it now in the final. Usually in that trial, you only have two companies. They invited three in the beginning, and they excluded one. For sure, we were fighting for it, and we could manage to stay. We are now with one American company in the final trials. We do not know if we can win that, but only this gave a shock moment into the entire American firefighters market because it was clear it is American-based, and that is now a German company is entering into the trials on the biggest and most important fire department in New York. That was interesting. Now we are fighting. Please cross fingers for Dräger so that we can make it also through at least the receiving the order. Defense. The geopolitical conflicts are pretty much known.
I think nobody has to explain what Zeitenwende means at least. It means so many of our solutions are established at the defense, so at our forces, European forces, American forces. When you think about Navy SEALs, they are using Dräger equipment, I do not know for how many years, probably 30, 40 years. For so many years. We are a player there. We are established. It means when that scales up, the forces are coming back into Dräger. Where we are, I would say, one of maybe not potentially the most important company is in technology, CBRN, the very nasty gases. Very difficult to handle, needs specific expertise.
Now when you see the big programs from the big primes which are actually running, like Rheinmetall, KNDS, BAE Systems, Kongsberg, all these primes, this is our targeted customer group, because into their massive big systems, we are the partner to integrate CBRN solutions, for example. That is just one element. There are other solutions as well in these systems. Why is that so important? Why we want to play not only on, I would say, kind of commoditized material to the forces? That is long-term usage equipment. We want to stay long-term so that offers afterwards, after the initial sales, a lot of service, maintenance, calibration, that comes back for so many years. These materials stays very long in operation. We have here a number because that is a public number already, so that we want to triple our revenue.
I would say our funnel and our order book is in right direction, therefore we are very confident that this part will, yeah, will push us forward. Maritime and shipping. We have elements in our portfolio on our markets where our big customer groups, chemical industry, petrochemical industry, they are shrinking, they are going down. That means we are shrinking with them. We need to compensate. We need to build back to, I would say, our revenue ambitions. That means we have to open fields where we are not strong out of the history. This is the part which we put as a compensating element with a strong sales and service network. Reiner Piske will explain on that. I do not know. Shipping market, just to give one example. Actually, the order books in shipping industry, if you take oil tankers, is the highest ever.
600 oil tankers are in the books of the shipyard. 600. Never been that high before. They all need rescue equipment, firefighting equipment, gas detection. We have to bring the access to sell our equipment there. The access is depending on the service network. It is scattered, it is fragmented throughout the entire world. That means we need to be in the most important ports in the world when the ship is operating, because they only take you on if you can be with them later on. Therefore, we changed our direct sales model into an indirect sales model with companies with a global reach, and Reiner Piske will explain on that what we are doing there. Our portfolio, and that is the beauty on it, our portfolio is built for this. We have it.
We have all, I would say, regulations, we have all approvals which we need, that means that keeps additional R&D effort away from us. That means we really can leverage, we really can scale into this, I would say, on a very reasonable fixed cost base. Yeah, but we need the global presence. Energy transition, clean tech. I have said already some words, I do not want to go too long into that. It is infrastructure, it is H2, and for an H2 molecule for our sensors, we have to make infrastructure safe, and it does not care if that is green, purple, or gray, yeah? When LNG moves out and H2 comes in, still you need a gas sensor to protect the infrastructure.
Yeah, and also then in these, we see it here as well, that we have the systematic that a long-term or long-lasting installations are done, that means we stay with service and recurring business in there. What does it mean to us in terms of technology? Because we have to put the right technology into these customer groups, industry segments, and applications. Digitalization is there, will not go away, and also our customers are moving stronger into this. That means we developed the IoT gateway for all the Dräger gas detection. On that picture, you see a control station, you see a mobile gas detector, a fixed gas detector. All this data has to come in one system.
So, and at least it's a cloud-based application service, which at least provides the opportunity for our users, for our customer groups to curate their data, to visualize the data, to analyze, and to improve their performance on safety and productivity as well. So that's the base, that's the ecosystem where it starts with. The ecosystem does not stay only at the industry. It goes over to fire service as well. Protecting people in harsh environment, firefighters, it's work, it's their job, it's a workplace. They fight fire, and it's their workplace. And our ambition is to make it more safe. We have here an example. The biggest fire department in Europe is Paris Fire Fighters . We were able to bring them to Dräger in 2025. It was for sure, it was a huge order, a lot of hardware, 1,400 SCBAs, lots of other elements.
But the key element was that we have the FireGround systematic. You see it here on that little tablet. That is the command center, and the commander outside at an incident area takes the data from his firefighters onto this data. So, these guys are under high stress. They are under high physical stress. If something happened, they can send help immediately. So they get real-life data about do they have enough breathing air? I would say the analog systematic, if you have an alarm whistle, and then the next to you hears it, but now someone outside sees it. The alarm whistle is still there, yeah? But, that's the digital thing.
And that evolutionary develops further as an ecosystem as well, so that you can get later on gas measurement data in so that you have one system to protect and to have an overview about your incident area where you work. Fire departments like Paris or other big ones, these are technology-driven, I would say, organizations. They force us because they have their own interest in that. And with our strategy, building on that principle, technology, and protecting people , that is what resonates with them and helps a lot to win here in that example last year, the biggest fire department in Europe. Coming back, digitalization, hardware, software, training, that has to be combined and comes together into our Omni systematic.
Omni systematic respects the wish from our customer groups that the CapEx systematic, when they come under stress, financial stress, they move more into OpEx systematic, and they ask for managed service instead of, "I own my fleet." They automatically don't want anymore to own the fleet. It's a movement from that in the other way. Is that a big bang movement? I wouldn't say no, but it's a trend. And our answer to that trend is combine these solutions together, and we build up a subscription-based bundle solution. So it bundles hardware, software, services. How can we play out that strongly? Because we have that very direct sales and service access to these customers, and they listen to us because we have direct access in these areas. So we build together with them their systematics.
Then it comes something to me in the past was a bit of the beauty and the devil thing, yeah? The devil was, we have these R&D DNA, long-lasting, heavy, and a little bit expensive in manufacturing cost, European German engineering. But now it pays definitely out, yeah? Because when we send a fleet to someone who has that bought as managed service or booked as managed service, we can keep our material long time in the loop. So we do not have to take it out every second year because we have long-lasting material. And there we have excellent statistic. Also here, the digitalization and the data helps us to really review that, and we know that we have significant longer lifetimes than our competition. And that makes us very confident to be successful in future also here.
Now I would like to hand over to my colleague, Reiner Piske. Please, Rainer, welcome here.
Thank you, Rainer. Ladies and gentlemen, let's turn now into our third strategic lever, and let me explain a little bit and illustrate what are geographically here our priorities. I would like to start, if I have the I would like to start again with the United States. The U.S. is actually the world's largest safety market, characterized actually by high standards and also a strong competition, mostly coming directly from the U.S. But we still see significant growth potential by expanding here our market access, strengthening our customer relationship and intimacy, and also leveraging scalable go-to-market models. First, we're broadening our reach through an enhanced channel strategy, which enables us, on the one hand, to expand our reach, but also with this approach, to keep or to maintain a disciplined cost base.
As Rainer said, there are major fire departments, but also key accounts across industries remain our strategic focus. With our hybrid sales model, we are actually able to understand deeply their evolving demands while serving them through their preferred sales channels. Defense in the United States is an additional opportunity. We are already, since many years, a trusted partner, not only of the Navy, but also of all armed forces here, and will further expand our presence through more channels, such as primes. Beyond equipment sales, we want to grow in recurring revenues through services, rental offerings, and digital offerings. Our aim is here that we expect a net sales growth of 6%-8% in the U.S. between 2025 and 2030. Let me give you an example to illustrate this highly aggregated version a bit more. Using now the example of how we expand the channel.
The U.S. fire market is a good prime example on how we scale that here. Following the North American approval of the AirBoss system in 2025, we partnered in the beginning of this year with MES Life Safety, which is the largest SCBA distribution network across the United States. This immediately expanded our reach in the market through more than 300 sales and service professionals from MES, giving us even more access to the 30,000 fire departments we have existing in the United States. Combining this around 70 partners we have already working for us, and we can really say leading product portfolio in this area, this significantly strengthens our market presence in this area, creates a powerful platform for accelerated growth here in the U.S. fire and rescue, and also in industrial safety. APAC.
Also here we have attractive growth opportunities driven in APAC by the industrial expansion in many countries, urbanization, and rising safety standards in many countries. Competition is strong, not only by the well-known international and mostly American competitors, but by many local competitors which might compete aggressively on price. To capture our potential here, we focus on three priorities in APAC: localized portfolio, stronger partner management, and an accelerated service expansion. Together, these actions or these four key actually are the foundation to deliver the 6%-8% annual growth through 2030 we have as our target. Again, one illustration, and here I also use the channel management, which is a key enabler of our growth strategy in APAC, a more professional and scalable partner network. Today, we have around 50% of our net sales in safety in APAC is going through indirect channels through sales channel partners.
We are shifting here from a very broad base to a fewer, stronger, better-managed partners under a common regional framework, and we also target to increase the share of indirect sales in the region. By this, we want to expand our market coverage, improve our execution quality, and provide also for us greater flexibility as the demand in the market evolves and this might be also in the future here and there volatile. At the same time, partner-led service capabilities help us to increase recurring revenues and build therefore a more resilient earnings profile. Coming to Europe. Europe remains the backbone actually of our safety business and also as a major earning contributor already today. We will leverage our, in many markets here, very strong market position while adapting also to the shifting demand patterns in different industries in Europe, as we all know.
The market environment is changing whilst, for example, currently the government spending on defense is rising significantly, creating additional opportunities for us. The demand in other industries such as oil and gas and chemical industries remains subdued in Europe. It's not everywhere the case. We will accelerate in Europe our growth in defense and government markets through dedicated commercial resources and targeted market developments. Initiatives for large accounts, we also expand our digital solutions, Rainer just described, helping customers actually again, like in medical, to improve their productivity, their own productivity, and also we enhance our own sales productivity through optimized channel structures, automation, and digitalization. This focused approach strengthens actually our market, expands our recurring revenues, and supports our targeted growth of 3%-5% through 2030. Talking a bit about defense also here in Europe.
Rainer mentioned already, Dräger protects military personnel on land, at sea, but also in the air. We offer quite a broad range of portfolio here. We offer respiratory protection, gas detection, military diving equipment, and even medical technology, for example, for field hospitals. It is across the divisions also. It ranges also from simple products like military masks and filters or SCBAs to more complex solutions based, developed sometimes together with primes or the customers. We are really able to do here quite a lot. To capture our growth opportunities in Europe, especially with the European NATO countries, we have established a dedicated sales organization for defense with former military professionals, mainly in sales specialists for the army, the navy, and the air force, who understand actually the customer's needs.
We provide also relevant conditions here in Dräger for the defense business, such as a framework of handling classified information. Our route to market here combines the direct engagement with armed forces, our partnership with major defense contractors here in Europe and also elsewhere, and we integrate basically our technology into their platforms. We have also close dialogue with government stakeholders, which is supporting our market access here. This positions us for both single equipment orders, but also for our participation in larger defense programs. Partnership in maritime. As Rainer outlined, these partnerships are here an important lever to expand our presence in the maritime industry across the world. In 2026, we partnered with Viking, which is a global provider of maritime safety solutions headquartered in Denmark.
The partnership covers actually a broad range of the Dräger safety portfolio and we are leveraging ourselves then via Viking's global network of 280 service stations worldwide in many of the major ports, providing access to over 25,000 vessels under contract with Viking. Another partner here we have already for a while is Poseidon. This is also a leading marine services and safety solutions provider headquartered in Greece, in Piraeus. Here we intensified last year our relationship and agreed on a joint strategic roadmap, creating also a good foundation for accelerated growth we have already in 2026 and also towards the future. Over time, we will build more partnerships in this regard to grow our global network and expand our access in this industry globally. Pricing also I would like to mention. There was already a question here.
Also, let us say in safety, pricing is an important lever for us, a powerful lever. A few years ago, we professionalized our approach to pricing in collaboration with Simon-Kucher, the leading global consultancy for pricing, monetization, and revenue growth. Today, we manage our entire pricing cycle from target setting, performance tracking, to active steering with a market-specific focus to drive growth, optimize our margins, and also get lifecycle gains. We equip also our sales force with respective tools, including nowadays AI-powered tools for pricing recommendation to realize actually our pricing targets. This structured approach was actually a very important key success factor in improving our result in 2023 and gives us also supports us in the future to navigate through challenging economic environments. Now, back to Rainer.
Thanks again. So there's the slide mover. Okay. Then I go to the last part of the presentation. So now we've talked a lot about the outer environment of our business. Now we have to have a look inside. So that means continuously driving efficiency, and what can we put under the umbrella of operational excellence. On one side, we have an own supply chain. We run factories, we run logistics, and we need to have a good procurement system. So that we put under an umbrella of the so-called Dräger Value Creation System. It's the base, at least out of lean manufacturing, Six Sigma principles, and that all comes out of the Toyota Production System.
Well, that gives us the base for a huge part of the organization to work continuously on state-of-the-art improvements, and that pays into a continuous improvement on our cost base and manufacturing cost. Now we have an additional lever that is for sure a reduction of direct material cost. We continuously have to work on that, and that goes together with the operations part, and you will see it a little later also in the R&D element. So that means clear-cut, defined targets behind that, clear-cut deployment plans, what at least contributes to our, I would say, profitability improvement. The global manufacturing network we use as well under the consideration of what's the best benchmark situation, where to move that, and we use our manufacturing system not only for better direct labor.
We use it also for better indirect labor ratios, because we believe, we are convinced that the production itself comes together with elements like industrial engineering, MRP, lifecycle management, and that can only come where the production is. So we move, we trigger the movements out of, I would say, the high-cost countries and the lower-cost countries based on this, when we can bring also the indirect part. That's essential. The other element, redesign to cost. As I said, our products are long-lasting products. They stay long in the markets, and usually it's very difficult then to change something in the design which leads into better material costs. So that means we have put an organization in place triggering redesign to cost programs. So we actively open existing products for redesign to position our cost better. Also here, very clear-cut measures behind it, what the contribution is.
In R&D, for us in R&D is very important so that we speed up, that we are faster than in previous times. With the speed, it comes the efficiency and the better, faster time to market. That's where we use for definitely all the AI tools. I wouldn't say it's totally something extra. It's already part. It's integrated in the DNA of our R&D teams. They use it as daily routine. So that's important, and we see the very good results specifically in the software development, what speed is there. For sure, we have out of our regulated systematics and where we have to follow the compliance rules, we use the AI also for all the elements of the testing, of the documentation to be ready for approval. Then the R&D footprint comes more also about demographic changes.
Access to people is the most important thing, and we follow the same principle than the medical. That would be, I would not elaborate that deep in there. It's the same principle. We're using the same area in Lithuania, the same company, software engineering, and that is the part where we move forward on our R&D efficiency. Then there's another for you. SG&A plays a vital role as well.
Thank you. Yes, now briefly about SG&A efficiency, which we are driving through more efficient sales, service operations, and administration. Here, I briefly outline what we do where, in which area. In sales, as I have described already a bit, we are optimizing our sales channel partner approach, aiming for more coverage with less or fewer fixed cost. At the same time, we are developing our direct customers further, aiming to increase our share of wallet with them, whilst not simultaneously building up too much resources. Then we also strive to increase efficiency in the way on how we conduct business. By 2030, we want to have 25% of safety net sales targeted to come through digital channels. Last year, we had around 5%. This year, we can almost double it, and 2030, 25%. For scalable operations, we automate fulfillment and order processing, optimize logistics and supply chains.
In service, our project delivery, streamlined processes, and digital AI-enabled and connected solutions will improve our efficiency here, also measurable. Also, in central administration and back office, we have respective programs in which automation and streamlining plays an important role. We maintain strict headcount control in these areas and align our global footprint, aiming to increase efficiency. Just one example in regards to what we mean here with footprint in these areas, we have closed recently seven sales and service locations in Germany, as an example, how we do that. Together, these measures align actually capacity with business needs, improve productivity, whilst keeping the organization focused on customers and profitable growth. Back to Rainer.
I will take the closing elements or the last slides. We talked already about the M&A part. Here we have an element which is included about M&A. Is there anything we sell off? We're going and separate. I think one important element there is we're not considering it only because it's not profitable we sell it. Is it strategic or non-strategic? Even if it can be profitable, it can be non-strategic. Then we start the thinking process, should we move it away? Should someone else operate it? Because strategic cannot be for us that we have a chance with reasonable investment, reasonable effort to scale it up on a global scale. If not, I would consider it's not strategic. This is the, I would say, these are some of the parameters we consider elements. We talked already, fire detection systems in Netherlands.
It was characterized as non-strategic U.S. offender program. MSI, you said already, and we have a long and a short list where we are going through. These are not massive revenue lines we are selling off that sometimes one-digit million, a little lower, two-digit million, but that is the area. When it comes to the question, should we add on something, then it is always the question, has that a clear strategic fit for us? We have an observation principle. We have teams running, observing markets where it makes sense to invest. So far, we have, I would say, no total hot topic for us, but it is a continuous program. Why we are doing this, because at least to let it go sometimes means when we cannot scale it up, it still covers resources.
It does not keep us on focus sometimes, because then we have to work on elements which are not strategic, and that we want to avoid. That is the reason why we do separation from several of these topics. Now to sum it up on the midterm targets, taking the history into account, coming from more difficult times, I think we have shown in the safety division, some years continuously that we are stable, we stabilized, and we are continuously growing. Now we want to add on another EUR 500 million on the revenue base of EUR 1.5 billion, summing up to EUR 2 billion in 2030. The CAGR assumption is 6% CAGR. We are very much confident that we can outperform the 4% market growth in the areas where we are.
When we compare that with our competitors over the, I would say, recent quarters, the last two years, I would say, we see that we have that track record already. If that comes together, it will provide us an EBIT margin of 14%-16%, and that is definitely our ambition. I have a good team behind it, Reiner and myself. We will push for that. Then, at a certain point later, we may meet again, and we made all this. Here you have a little bit the assembly principle, where it comes from. I do not want to go too much in the detail. That would just be repetition then. Thanks for listening to me, safety division, and sorry for a little bit out of time. Now we have the chance for interim moment for the Q&As. Thank you.
Thank you. As you said, we are running a little bit behind time, but still, of course, we will jump right into Q&A. Christian, please.
Yes, thank you. When you look at Europe and the market growth of 3%-5% CAGR, given the headwinds you talked about, declining industrial base, declining pharma industry in Germany and in Europe, how do you expect to manage this kind of growth going forward? Because it sounds more like maintaining a flat development.
Yeah. We have to compensate the declining sectors with more growth in other sectors. Here, for example, defense, we mentioned as a significant contributor to that growth, and also other focus markets which have been presented by my colleague are here relevant, that we actually overcompensate respective declines. Altogether, we are quite confident that the 3%-5% we are going to achieve in Europe.
Thank you.
If I may, I would like to then right jump into one of the questions from the webcast because that fits quite well, Reiner, and that is on APAC, the growth in APAC that we have seen. Actually, it was a question for medical, but it also applies to safety. You already touched it in your presentation with the channel partners, but maybe you could elaborate why APAC should grow stronger than in the past.
Yeah, let me start with the more challenging part, which is in medical. Clearly, the decline in APAC in 2023 and then towards 2024 was mainly due to China. Here, China played a major role. We believe now we have reached the bottom. With everything what we are doing here currently, a stronger localized portfolio, working also together with, let's say, government authorities like the health bureaus, or I was also participating in a travel with our minister, Katherina Reiche, to address actually the challenge of the restricted market access for medical technology in that market. So we have actually prepared ourselves quite well, and here, this explains a little bit that we expect moderate growth again in China, but we have a track record already in the other area or in the other sub-regions such as India, where we had already a good growth.
This comes then together. We have no longer China declining the overall picture, so we are confident actually that we can move here in this growth scenario. This is, I think, the point. In APAC, in safety, we had also challenges here in China, however, not to such a strong extent compared to medical.
Thank you. Any questions from the room? Oliver?
Yeah, thanks very much. I am not sure if I missed that. Have you quantified the share of recurring revenues, and is there any kind of targets that you can share, and any kind of sense what the kind of margin gap is here in terms of how superior it is? Secondly, if I look at the profitability of MSA, it is north of 20%. I mean, I just want to get your sense, what are the kind of key deltas in terms of product region mix, anything else that you believe is explaining this gap? Thank you.
I am going to start. The share of our medical services is around EUR 300 million-EUR 400 million out of the overall net sales in safety.
About the question about our appreciated competitor, MSA. Yeah, absolutely a fair question. They report very high EBIT ratios, much higher than we are. Let me start with the first. Coming out of the history where we have seen ourselves, now with that improvement, I would say first to make it a steady, robust improvement so that we can invest more. That is our actual strategic movement until 2030. If we would make a plan saying we are going same level than the others, I doubt if you would believe me, number one. Secondly, I doubt our employees would believe us. We should not rocket that out that early. That means we compare at the moment German industry, German-based, and if we end up on 14%-16% 2030, I am not saying it automatically has to stop there, but do first things first.
I personally believe we are in a very stable and well-positioned environment if we take that comparison, and that is how we run this organization for the moment until 2030. There is a second number, which to my opinion is also very relevant. That is the return on capital employed. If we make the simple rationale on that, we take MSA and take Dräger, and we are far ahead in this. That is what we are looking for now.
Thank you. While we are at benchmarking, maybe Toni, do you want to take the question here left over from the first Q&A, which is the question on the profitability gap in the medical, and if there are some structural reasons for this gap?
Two or three parts of the answer on that. If I look at the today's peer performance, there are significant relevant peers who are also not reaching the 10%, just to be clear on that one. Yes, there are some of them who are significant above. A second part of my answer is, and yes, of course, we are also further, let's say, working on going to the 10 percentage points, but we have to also be aware that we have to show now in 2027, 2028 that the ramp-up, the significant ramp-up in our monitoring business come through. This is the second part of my question. And the third is, not the biggest one, you have to also be aware that some of the key competitors have a very strict or a very, let's say, aggressive way of how do they activate R&D costs, which we are not doing.
Thank you. Further questions from the room regarding the safety presentation? That is not the case. That is positive because then we can catch up some time, and we would now have a break for lunch and rejoin at five minutes to 2:00 PM for the next part. Thank you very much.
[Non-English content] .
The afternoon session with the CFO, Gert-Hartwig Lescow, guiding us through the financials.
Thank you, Tom. Also, thank you very much, all of you, for joining us today and for spending your day with us. It is a true pleasure to present to you how the different elements that my colleagues have outlined in medical and safety, how we are going to capture those and how these come together in our financial ambition, and how we are going to translate the growth and the higher profitability into long-term shareholder value. It is an ambitious guidance. Sorry, it is a demanding ambition, as I think some of the questions for the medical have already demonstrated. But we believe it is built on the progress that we have made over the last two years. We want to build a business that can invest in growth, deliver attractive returns, and remain financially resilient through the different market conditions.
Let me start with the key figures for our Ambition 2030. Our Ambition 2030 combines the continued sales growth with a substantial improvement in profitability. We aim to increase our annual growth net sales by around EUR 1 billion- EUR 4.5 billion by 2030. We also want to raise our EBIT margin from 6.7% in 2025 to between 10%- 12%. This represents an average sales growth of around 5% per annum between 2025 and 2030, with medical growing by around 4.5% and safety by around 6% a year. Profitable growth and greater operating efficiency will support the margin improvement while we continue to invest in innovation and maintain a strong balance sheet.
From 2027, operating profit under IFRS 18 will become our leading profitability measure, and we will retain the same numerical ambition ranges. I will explain the transition after reviewing the margin drivers. Let us first look on how the two divisions will contribute to our sales growth. Medical and safety are each expected to contribute equally to the EUR 1 billion in additional net sales. In medical, we aim to grow 2- 3 percentage points faster than the market. We will build on our installed base to increase recurring revenues and expand our solutions business. In safety, we aim to continue growing faster than the market by expanding in selected focus markets. These include U.S. fire services, defense, maritime, and shipping, as well as energy transition and clean tech. Our focus is on profitable growth.
We want to capture customer demand and translate it into profitable sales with a strong contribution from services and recurring business. Delivering these plans requires coordinated execution across our divisions, regions, and functions. I would now like to take a look at how this growth, together with the improvement in operating efficiency, will translate into a higher group margin. We previously communicated our goal of reaching an EBIT margin of at least 10% by 2030, and our Ambition 2030 now sets a range of 10%-12%, reflecting the additional potential we have identified in our detailed planning. Building on the 2025 margin of 6.7% requires profitable growth and greater efficiency across the businesses. Toni Schrofner, Rainer Klug, and Reiner Piske have explained three areas will contribute to this improvement. First, innovation and productivity is expected to contribute around 1- 3 percentage points to a higher gross margin.
The main levers are pricing, lower direct material cost, and improvements in our global manufacturing network, particularly in India and the Czech Republic. Second, R&D structured efficiency is expected to contribute around 0.5-1.5 percentage points. We will improve development efficiency through common platforms, greater reuse, changes to our R&D footprint, including stronger capabilities in India and Eastern Europe. These measures will strengthen our innovation capabilities while maintaining our high-quality standards. Medical will make the larger contribution, as R&D expenses currently account for a higher share of sales than in safety. Third, SG&A optimization is expected to contribute 1-2 percentage points. This includes disciplined headcount management in administrative functions and greater process automation, supported by AI. Our objective is to keep functional expense growth below sales growth.
Implementation of some measures will take some time, particularly as we build up development capabilities at additional locations like India or Eastern Europe, and we therefore expect a greater share of the expense efficiency benefits later in the period. The contribution ranges are indicatives, and their endpoints should not be added independently. Our group ambition reflects the combined impact of these measures and the underlying business development. Brief sideline, we have introduced our Ambition 2030 using the EBIT, the profitability measure you know from our reporting. From January 2027, we will adopt IFRS 18, which introduces operating profit as a defined subtotal in the income statement. Operating profit will become our leading profitability measure for management and external reporting, and we will discontinue EBIT reporting. This continues our approach of using unadjusted measures from the audited financial statements wherever possible.
For Dräger, the difference between the two measures is generally small, although it can, of course, vary from year to year. For 2025, for example, our reported EBIT margin was 6.7%, compared with 6.5% on an IFRS 18 operating profit basis. We retain the same numerical ambition ranges on the new measurement basis, 10%-12% for the group, 7%-9% for medical, and 14%-16% for safety. Let us now take a closer look at how gross profit and functional expenses will contribute to reaching our ambition of achieving an operating profit margin of 10%-12%. We have continuously increased gross profit and gross margin since 2023. By 2030, we aim to achieve a gross margin of 46%-48%. Our focus is on further strengthening pricing power and improving direct cost efficiency. Pricing power starts with the value of the products and services we deliver.
We will strengthen value-based selling and use more systematic pricing tools to reflect that value in our prices. On direct costs, we will pursue supplier cost reductions, alternative sources, and value engineering. These measures must protect the quality, reliability, and performance customers expect from Dräger products. Together, these initiatives will support further gross margin improvement and contribute to our group profitability ambition. Let's now turn to functional expenses and how we intend to keep their growth below sales growth. Functional expenses have declined as a share of net sales since 2022 and remain below 39% of net sales over the past three years. By 2030, we aim to keep expense growth below sales growth and to reduce this ratio further to 35%-37%.
Within the total, we aim to bring the R&D ratio from around 10% to around 8%-9%, and we want to lower our SG&A ratio from around 29% to around 27%-28%. Continued investment in innovation and customer-facing capabilities remain essential. The aim is to direct spending towards areas with the strongest strategic and economic contribution while increasing productivity throughout the organization. We will also use automation, digital tools, shared services, and more efficient routes to market. The measures outlined by my colleagues in manufacturing, development, sales, service, and administration provide the basis for delivering these efficiencies as the business grows. Together with the gross margin improvements, this expense discipline underpins our profitability ambition. Let's now turn to working capital and how we support cash generation as the business grows. High profitability and disciplined working capital management both support our cash generation.
Since 2023, we have reduced days of working capital, supporting cash flow and limiting the capital required to fund our business. As sales grow, we aim to keep days working capital stable. Regional growth patterns matter. Some markets require more working capital relative to sales than others. Where these markets grow faster, we aim to offset the additional requirements through timely collection of receivables and effective inventory management. This requires close coordination across the business, and our objective is to maintain product availability and customer service while using capital efficiently. Let's look at how profitability and working capital discipline contribute to free cash flow. As Stefan Dräger emphasized, profits must also translate into cash inflow to preserve our long-term financial resilience and freedom to act. A strong free cash flow is therefore as much a part of our ambition as profitability itself.
Free cash flow has increased significantly in recent years, supported by higher profitability and effective working capital management. Our ambition is to sustain strong cash generation as the business grows. We will build on this progress through disciplined working capital management and careful investment decisions based on expected economic returns. Generating free cash flow is also a key metric in our variable compensation, alongside Dräger Value Added. Let me now explain how the DVA helps us to assess whether our growth creates value. We aim to generate operating profit that exceeds the cost of capital employed in our business. Dräger Value Added, or DVA, measures the surplus in euros. Our goal is to deliver a positive DVA every year. In 2025, the DVA increased by EUR 36 million to EUR 90 million, mainly through higher earnings. By 2030, we aim to increase it to more than EUR 250 million.
For the DVA to be positive, our return on capital employed must exceed our weighted average cost of capital. Around 14%, our ROCE already exceeds this threshold, and we intend to build on this progress and increase the ROCE to approximately 20%+ by 2030. Higher profitability and disciplined capital management will drive this improvement while we continue to invest in future growth. Effective working capital management and careful assessment of investment returns are important elements of this approach, and I would like to show how the capital allocation supports that profitable growth. Our capital allocation approach begins with a strong balance sheet. We aim to safeguard our investment-grade rating and maintain the liquidity and financial flexibility to execute our strategy. Organic investment is our priority. We invest in capabilities, capacity, and efficiency to support profitable growth.
Selective M&A can complement these investments where there are strong strategic fits and attractive expected returns. We also return capital to shareholders through dividends, and our policy provides for a distribution of at least 30% of consolidated annual net profit, subject to an equity ratio of at least 40%. Our capital allocation is guided by long-term shareholder value. We invest in profitable growth and return cash to shareholders through dividends while preserving financial resilience. Financial resilience is the foundation of our capital allocation. A strong balance sheet provides the financial flexibility to invest in the business and return cash to shareholders. Since 2023, our ratio of net financial debt to EBITDA has improved substantially and remains at a healthy level. Our equity ratio has also improved, exceeding 50% in 2025, and this is comfortably above the 40% threshold in our dividend policy.
This financial strength supports our investment plans and provides resilience as market conditions change. We will preserve the liquidity and flexibility needed to execute our strategy while safeguarding our investment-grade rating. Let's now take a look at our organic investment or priority for profitable growth. The organic investment is our first priority for profitable growth. Our strong balance sheet gives us financial flexibility to fund the capabilities needed to deliver our ambition. Investment intensity measures the investment in relation to net sales. For 2026- 2030, we expect to invest between 4% and 5% per annum of net sales, slightly higher on average than the 4.3% that we have invested in the last few years on average. These investments will strengthen the capabilities needed to support our growth ambition and improve operational efficiency. Our profitability ambition goes hand-in-hand with investing in the long-term development of our business.
At the same time, investment discipline remains essential. We assess each project against its strategic fit, its expected economic contribution, and the timing of returns. Capital must, of course, be linked to the measurable benefits. Let me illustrate this with two targeted projects in Lübeck that will strengthen service delivery and development capabilities. The Global Service Center will combine existing service centers, product take-back, and demo equipment activities for medical and safety. It is planned to begin operations by the end of 2029. The aim is to shorten service turnaround times and provide the capacity to scale service delivery as our business grows. The second example, the Safety Future Lab, will provide R&D facilities and a design center for customer workshops and product demonstrations. Construction is expected to take about 30 months, with a planned opening in 2030.
This investment will strengthen our development and testing capabilities and support closer collaboration with customers. Both projects link investments to specific operational outcomes, service capacity and responsiveness in one case, development and testing capability in the other. The same discipline applies to acquisitions and other portfolio investments. Let's now turn to how selective M&A can complement our organic growth. Selective M&A can complement organic growth when it accelerates innovation, closes portfolio gaps, or improves time to market. We consider three broad categories. First, acquisitions that expand our product offerings or close specific portfolio gaps. These can add complementary products faster than internal development when the strategic fit and economics are compelling. Second, technology and startup investments. These can provide access to innovative technologies and business models that strengthen Dräger's core business or extend it into adjacent areas. Third, divestment of non-core or low-return activities.
Exiting such activities can reduce complexity and recycle capital into higher-return priorities. Every transaction must offer a clear path to long-term shareholder value, and again, we assess strategic fit, build versus buy, integration capability, or risk-adjusted economics. Our acquisition, our focus is on smaller, targeted transactions that complement our core business. Let me illustrate this approach with past transactions and the areas we are considering for future investments. In recent years, our portfolio investments have focused on expanding our product offerings and adding complementary capabilities, including in adjacent businesses, minority stakes, and startups, also creating options for future growth. Divestments helped us to focus the portfolio and redeploy capital to higher-return opportunities, and the recent examples that Rainer Klug and Stefan Dräger gave include the Dutch fire service business and the divestments of the U.S. interlock business, while retaining the global product business.
Looking ahead, potential investment areas in medical may include automation in acute care, medical device connectivity, hospital consumables and accessories, digital health application, or software. In safety, areas of interest may include personal protective equipment, respiratory protection, impairment check products, gas and flame detections, lone worker solutions, and defense applications. These areas guide for search opportunities. Any investment or acquisition must meet the strategic and financial criteria I've outlined. We will continue to strengthen our capabilities, focus on our portfolio, and look where we see potential for long-term value creation. Would like to take a look now at what the successful means for earnings per share. Successful execution of our ambition will deliver substantially higher profitability and earnings per share. We completed the simplification of our capital structure following the notice of termination of the last outstanding participation certificates in 2021, with final settlement in 2023.
The associated profit-sharing obligation has ended, so any improvement in profitability will now benefit shareholders in full. Achieving our ambition implies a compound annual EPS growth of around 18%-22% between 2025 and 2030, so earnings per share would more than double over this period. Higher earnings also provide, of course, the basis for higher dividends under our established policy. Let me now take a look at that. As I said, the policy links cash distribution to the earnings. Higher profitability provides the basis for higher dividends, and the policy provides for a distribution of at least 30%, subject to an equity ratio of 40%. It's a minimum payout, not a fixed ceiling. Our strong earnings development has already supported a significant increase in total distribution in the past three years.
We will retain capital to invest in profitable growth and build long-term shareholder value while returning cash to shareholders through dividends, and we believe a strong balance sheet will support both. Let me now bring together the key element of our financial ambition and capital allocation approach. Our ambition is to reach annual net sales of around EUR 4.5 billion and an operating profit margin of 10%-12%, supported by strong cash generation and return above our cost of capital. Our capital allocation framework turns operating profit into shareholder value through four priorities. First, financial resilience. We remain the balance sheet strength and liquidity needed to execute our strategy. Second, organic growth takes priority. We fund growth and efficiency investments with measurable economic benefits out of the existing cash flow. Third, selective M&A. We add complementary capabilities and focus our portfolio, guided by strategic fit and attractive expected returns.
Fourth, dividends. We return cash to shareholders through our established dividend policy. Higher profitability, strong cash generation will provide the financial capacity to pursue these priorities. We put the capital to work through disciplined investments and return cash through dividends, with long-term shareholder value guiding our decisions. At this point, I would like to thank you. Before I hand back to Stefan Dräger, I think we will have another session of Q&A, and we are looking forward to your questions.
That's right. Thank you, Gert-Hartwig. Our final round of Q&A now. First, we start with questions in the room, please.
Yeah. Thanks a lot. My name is [Eric Grüncheidt], and giving the expected future cash flow trends, what measures we investors can expect more? As you said, already mentioned the 30% payout ratio minimum. What is your stance on share buyback programs and its possible cancellation of the repurchased shares? I think especially in regard to the weak, yeah, common stock at the stock exchange. My second question would be for Mr. Dräger. You just spoke about Dräger's long-term strategy, and in particular, the important role of the family. They stand for the stability and cross-generational perspective. I'd be interested to know if the next generation is already in the starting blocks. Is it already actively integrated into Dräger's corporate structure?
Thank you for your questions. I think the first question is for you, Gert-Hartwig.
Thank you very much for your question. It is, of course, a very valid and very good question. Going forward, the priority is on building our business along the priorities that I have outlined. We will distribute 30% of the resulting net income to shareholders. We have no plans at this point to complement that with a share buyback, as you propose. We do have the approval from our general assembly. We may come back to that, but as I said, there are no concrete plans at this point to do that.
In addition to this first part of your question, if you think about share buybacks, then you rightfully mentioned the ordinary shares with voting rights are trading, say, with quite a distance below the preferred shares. However, if you think about a buyback on these bonds, there is a limitation. If I buy back them myself, there is a legal, say, threshold. I shouldn't be above 75% free float, must not be below 25%. This is even more unlikely to happen compared to a buyback on the preferred shares. On the long-term strategy for the family, yes, that is the plan to secure the freedom to operate for more generations to come. Yes, the sixth generation is already preparing, and stay tuned.
Thank you, Gert-Hartwig. Oliver has a question.
Yeah, thanks very much. The first one would actually be on phasing. I mean, it is quite some significant growth that you are outlining here over the coming years. I think you indicated some measures are a bit back-end loaded, but can you provide any kind of more color on this phasing, and can we actually expect any kind of margin improvement next year? You have the kind of refunds, obviously, that are burdened, assuming we are coming out at the kind of midpoint of the guidance, just to get the expectation in the right place. Secondly, just on top line, everything starts with top line. Can you just provide some color? What is the embedded assumption in terms of volume price, potentially also mix? I assume that there is a kind of a positive pricing effect being involved.
And thirdly, if you just think about this kind of margin expansion potential, I mean, this is a kind of best case, or have you assumed any kind of safety cushion to counter basically for any unexpected events that always occur? Thank you.
Okay, so the first question I understand actually has like two elements in there. One, what's the timing? There are two key elements that go more towards, if you will, the later part of the period, especially from a portfolio point of view, as Toni Schrofner has pointed out. The re-emergence, for example, in the U.S. with the monitoring will contribute significant earnings potential, but likely in 2028, 2029, not quite in 2027. Secondly, while some of the measures will contribute to a higher efficiency right away, there are other measures that include relocation that will go more to the other end. So there is a tendency or, say, a bias to the later end on the period. We have not quantified that, and there is a bit of a variety in there.
The second part of your first question, I understood as, okay, so what does that mean for 2027? Will we see a margin improvement? That, of course, also depends on how do we come out in 2026. That is, unfortunately, given our seasonality, just a bit early. We still depend to a large degree on November and December. Of course, in our bandwidth, similar as this year, we aim to improve profitability and show some of that already in 2027. To what degree, by how much, we will see when we publish our preliminary figures for 2026. Your second question was, I believe, was that on the pricing or?
Volume mix.
volume mix, yes. There is, as you stipulate in your question, and there is a pricing and a volume element. In the growth, the larger part is expected to come from the volume growth versus the pricing. But there is a pricing element in there as well. So roughly a quarter, a third or so of our growth is, give or take, coming from pricing. The third question—
There was still one element on, is there a safety cushion in the—
The safety cushion. Well, there is not a safety cushion. I think your question was like for any eventuality. I do not know, since this is an eventuality that I do not know about, we had not planned for the war in Iran, we had not planned for the war in the Ukraine, so we have not provided for such events. Still, our plan is based on initiatives throughout regions, functions, and divisions, and is supported by many different elements. That in itself provides stability for the delivery, but there is a range in outcomes. That is why we provide the profitability ambition also in a range. So, we are quite confident that we can reach the profitability improvement, and I believe it is understood that if there is similar events like a war in the Ukraine that would need a reassessment of where we are.
We would still think that over the period, we can deliver improvements in the business.
In fact, this takes care of some of the topics that we have also received online, but there is still one aspect that I would like to switch now to the online question, and that is concerning the free cash flow in this current year, in Q4. We expect, due to our net debt guidance, to see a good Q4 cash flow development, and the question is, what is driving that?
Similarly as the strong seasonality, which affects profitability and has affected profitability in almost all years, we see the similar or the same seasonality in the cash flow. Last year's cash flow in the Q4 was actually exceeding EUR 100 million. We do not expect the same amount, and it is really a combination of strong deliveries in the fourth quarter, which is cash positive by the reduction of the inventories, and there is a counter factor from the receivables. But all in, it is typically strongly positive for this year, probably not quite as positive as it was in the last year.
Thank you. Maybe another question from the floor here? Yes, please.
[Foreign language]
You mentioned that you have an investment-grade rating and you try to sustain that. What kind of investment-grade rating is that? You are not rated by Moody's, et cetera, as far as I know.
No, that is a very good point. I should have been more clear that that is the synthesis of the assessment as it is played back to us, but there is no public rating available, and we aim to keep a robust financial standing, especially with our financing banks. We do not plan to apply for a rating by Standard & Poor's or any of the rating agencies.
Thank you. There seems to be no further question, so this would conclude our Q&A. I would now hand over to you, Stefan, for some closing remarks.
Ladies and gentlemen, this brings us to the end of today's presentation. As I announced in my opening remarks, our commitment to creating sustainable value will also be manifested in our compensation. Starting in next year, 2027, the variable remuneration of the executive board will be fully linked to the achievement of all three corporate objectives. That of the senior executives will be largely linked to these objectives, profitability, innovation, and connectivity. 70% of the executive board's bonus will be linked to profitability and cash flow targets out of corporate objective one. 40% of the short-term bonus, which is 20% of the overall bonus, is diverted to virtual shares with a five-year lock-up period. So eventually, after the ramp-up phase, a full bonus is linked to the share price. 15% each will be based on corporate objective two, innovation, and on corporate objective three, connectivity.
The changes to the remuneration system will be included in the agenda of our annual shareholders meeting on May 5th, 2027. Ladies and gentlemen, I would now like to conclude our presentation with a summary of the key takeaways. We are well-positioned for the future, delivering solutions to major megatrends through a highly diversified and resilient business model. Our clear mid-term priorities are profitability, innovation leadership, and expansion of our systems and recurring revenue business. Since 2023, we have consistently delivered on our commitment to improve our EBIT margin by approximately 1 percentage point per year. Looking ahead, Ambition 2030 provides further upside, and we are committed to achieving our new mid-term net sales and margin expansion targets through 2030. On behalf of the Executive Board, thank you for your attention. Again, we highly appreciate your participation.
Also special thanks to everyone who helped host this event and prepare this event. Now, with this, I hand back to Tom Fischler for further organization. Thank you.